REGISTERED CHARITY

NUMBER 223106

Royal College of General Practitioners

Annual Report 2018-2019

Research & Surveillance Centre

Weekly Returns Service Annual Report 2018-2019

Contents

Introduction

Welcome to the Royal College of General Practitioners (RCGP) Research and Surveillance Centre's (RSC) Annual Report for 2018-19. This is our 53rd year of surveillance.

For over 50 years, the RSC has produced a Weekly Return of respiratory disease and other infections and an Annual Report. The networks primary area of interest is influenza and influenza vaccine effectiveness.[1]

This Annual Report is based on data extracted from more than 200 general practices and draws together the principal elements of our work – disease surveillance, virological sampling, and vaccine effectiveness. It covers the period from the 7th May 2018 (International Standards Organisation (ISO) week 19) to the 5th May 2019 (ISO week 18) and includes the 2018-2019 influenza season.

Influenza surveillance is a significant part of our work. This is carried out by general practices through the network who accurately "code" the diagnoses of the patients they see with respiratory disease and other monitored condition into their computerised medical record (CMR) system. Coding ensures an unambiguous and searchable recording of a condition.[2]

Two of the most important conditions that our surveillance practices monitor are acute bronchitis, a good clinical signal of respiratory syncytial virus (RSV) in children under 5 years old at the end of the calendar year[3,4] and the peak of influenza A; and influenza-like illness (ILI), which although present all the year round peaks with circulating influenza.[5] We also ask member general practices to take virology swabs that are tested at Public Health England's (PHE's) reference laboratory.

There was also growing interest in serosurveillance, looking at levels of immunity in the population and their vulnerability to infection.[6] We felt that samples for sero-epidemiology and a serum bank could be very usefully co-located with sentinel networks.[7] These discussions led us to co-develop with PHE a pilot serological surveillance of influenza and other infections using the RCGP RSC network.[8] We recruited 8 RCGP RSC practices to collect blood samples which were tested for influenza antibodies. This will provide important information about background population immunity to certain infections, and we hope this surveillance becomes an activity of the network.

In addition to influenza surveillance, we provided a dashboard to general practices in our network for real-time feedback on general practice workload, chronic disease, data quality, and number of microbiological samples they have provided compared to the rest of the network. [9]

Based on RSC's virology samples, Influenza A subtype H1N1pdm09 was the predominant strain followed by Influenza A (H3N2) in the latter part of the season. Very little influenza B was observed in this season.[10] A similar pattern was seen across Europe.[11]

Influenza A subtype H1N1pdm09 was first detected in the network in ISO week 43 (week commencing 22nd October 2018) and peaked in week 6 (week commencing 4th February 2019).

Influenza-like illness (ILI) peaked in ISO week 6 (week commencing 4th February 2019). In this annual report, we set out our methods and key results for the year.

Methods

Overview

We report in the methods section the size of our network and how it has grown over the year of this report.

We describe our long-established collaboration with Public Health England (PHE) and our contribution as their principal primary care surveillance through microbiological sampling and other projects using this pseudonymised primary care data.

We also describe our data extraction processes and how we ensure good information governance.

Member practices and network expansion

The RCGP RSC Annual report period 2018-2019 started in May 2018 with 267 member practices and a population of >2.7 million patients (Table 1).

The RSC member practices and population doubled in size at the end of the reporting period with 505 member practices and a population of over 5 million patients (Table 1).

Over the course of the year in 2018, the RCGP RSC extended its role in surveillance and built a general practice workload observatory by doubling the population of the network to provide a picture of workload and complexity of cases seen in general practice.

The RSC dataset

Data extraction process and Information Governance

All RSC member practices have signed a data sharing agreement (DSA) agreeing to share data for SQUIRE (**S**urveillance, **QU**ality **I**mprovement, **R**esearch and **E**ducation) purposes.

Data were extracted twice weekly from member General Practices (GP) using Apollo Data Management Services, part of Wellbeing Software.

Data were pseudonymised (a process that scrambles any strong identifiers such as name, NHS number, and date of birth) as close to source as possible. This varies between different types of clinical systems used by GPs. The pseudonymised data were held on secure servers at the RCGP RSC data and analytics hub in the Section of Clinical Medicine and Ageing at the University of Surrey. Both Apollo and the University of Surrey are fully compliant with NHS data governance rules.

The pseudonymised NHS numbers and our pseudonymisation algorithm enable us to link data to other data sources at individual level, without compromising the privacy of individuals. This includes linkage to results held by PHE, hospital and death data and other disease registries.

Patients who opted out of data sharing, for any reason, were identified through an 'opt-out' code and excluded from our analyses by the automatic extraction process.

Reporting period for Annual Report 2018/19

This annual report used pseudonymised data extracted from RSC member practices with good data quality, who had a reliable data extraction that week. This annual report started with 163 practices (combined registered list >1.68 million) and finished the reporting period with a weekly return consisting of 250 practices (combined registered population of >2.5 million, Table 1)

ISO Week	Included in Weekly Return		Data Extracted		Signed data sharing agreement	
	Practices (n)	Registered List (N)	Practices (n)	Registered List (N)	Practices (n)	Registered List (N)
Week 19, 2018 commencing 07/05/2018	163	1,687,170	192	1,954,860	267	2,730,056
Week 18, 2019 commencing 29/04/2019	250	2,542,437	321	3,178,926	505	5,076,806

Table 1: Change in size of RCGP RSC over the period of 2018-2019 annual report. The practices included in the weekly return rose from 163 (registered population (N) >1.6 million) to 250 (N>2.5 million) across the period of the report. The number of practices where data were extracted rose from 192 (N>1.9 million) to 321 (N>3 million). Practices joining the network expanded from 267 (N>2.7 million) to 505 (N>5 million).

Working with and supporting Public Health England:

The RCGP RSC has worked in close collaboration for over 50 years with Public Health England (PHE) and its predecessor bodies, providing influenza and respiratory disease surveillance and vaccine effectiveness.[1]

The legal basis of our work with PHE is The Health Service (Control of Patient Information) Regulations 2002 which establishes a legal basis in England and Wales for data to be disclosed for public health purposes without patient consent. Our surveillance work with PHE is under Regulation 3, and some health promotion work under Regulation 5. The specific projects are individually approved by the PHE Caldicott Guardian, and then on an annual basis.[12]

Measuring Vaccine Effectiveness

The RCGP RSC is one of the sentinel surveillance networks across the UK contributing towards estimates of influenza vaccine effectiveness (VE). PHE uses the test-negative case-control (TNCC) design or cohort studies to estimate VE.[13]

Vaccination helps protect populations from disease and saves lives every year. Data from RCGP RSC practices is crucial for ensuring that vaccines are as effective as possible:

- The childhood flu vaccination programme was introduced in 2013/14 following a successful pilot.[14] This is also known as the live attenuated influenza vaccine (LAIV) programme. Data from RCGP RSC practices provided evidence that the pilot scheme should be rolled out across the country and is still being used to monitor the ongoing effectiveness of the scheme.
- Data from RCGP RSC practices are also utilised to monitor the effectiveness of the seasonal flu vaccine for adults.

Monitoring Disease Incidence

The RSC is PHEs principal primary care surveillance system for England. We reported weekly incidence of over 30 conditions specified by PHE.

We monitored over 30 communicable and respiratory diseases on a weekly basis. Our data feeds into PHE's surveillance system and gives an early warning of epidemics or unusual disease patterns. Our monitoring warns of seasonal events that may put pressure on health services, such as the start of the flu season, and allow services to be planned accordingly.

Our surveillance contributes to the Chief Medical Officer's decisions about when influenza is circulating. This triggers permissions to general practices to prescribe an oral antiviral medication, where they feel appropriate.

Collecting respiratory virology samples:

The RCGP RSC undertakes respiratory swabbing of eligible patients which forms part of the test-negative case-control (TNCC) design to estimate flu vaccine effectiveness. These samples are also used to estimate the potential strains that are likely to be in circulation in the following season, so that decisions can be made on the candidate vaccine virus to be included in the new season of flu vaccine.

The RSC member practices were involved in two microbiological sampling studies for this season; our standard virology sampling and for the first time a serology pilot.

As part of our work for measuring influenza vaccine effectiveness, RSC member practices took virology (nasal and throat) samples during winter.

The study population included patients presenting with acute influenza-like-illness at the general practice. Patients were verbally consented to provide a virology sample, with the samples being tested for influenza by real-time polymerase chain reaction (PCR). Cases were patients who had a positive PCR result for any influenza. Controls were any patients who tested negative for influenza A or B.

Additionally, we piloted our first serology (blood samples) collection which included opportunistic collection of samples from patients visiting their GP for a prescheduled blood test. [2] These samples were tested for influenza antibodies and became part of PHE's serum archive collection.

Other use of RSC Data

Identifying disparities

The RCGP RSC data allows us to explore disparities in clinical presentations of disease in primary care. Clinical data help us identify key demographic characteristics and at-risk groups, providing a strong basis for public health interventions. Flagging disparities has been an important interest of the network, both in terms of quality of care,[15,16] as well as access to services particularly as they digitise.[17]

Results

Overview

Our results summarise our sample population, monitored conditions, breakdown of our surveillance specimens and influenza vaccine effectiveness. Additionally we have provided appendices A, B and C showing weekly disease incidence graphs, data tables of monitored diseases and demographic distribution by conditions.

Sample Population

This section shows the demographic (age and gender) breakdown of our sample population, and how it compares with England as a whole. This report covers the period 7th May 2018 to the 12th May 2019 (ISO Week 19 of 2018 to ISO Week 18 of 2019). This includes all patients who were registered for at least one week during the reporting period, within a practice from the RCGP RSC network for which we received data.

Age-Sex breakdown by NHS region

NHS Region	Gender	<1yr	1-4yrs	5-14yrs	15-24yrs	25-44yrs	45-64yrs	65-74yrs	75-84yrs	85+yrs
South	F	4,104	24,561	66,101	70,497	148,493	152,214	64,081	42,456	24,110
	M	4,475	25,490	70,092	70,293	145,980	154,637	59,655	35,935	14,225
London	F	3,095	15,842	32,853	35,081	122,236	54,107	14,017	8,890	4,582
	M	3,282	16,361	34,209	30,933	119,998	59,904	12,500	6,894	2,694
Midlands	F	2,108	11,922	32,106	29,251	69,918	75,114	30,920	19,748	10,511
And East	M	2,265	12,736	34,005	30,482	69,084	76,047	29,094	16,981	6,143
North	F	3,694	19,322	50,341	63,968	119,305	114,746	47,163	30,284	15,222
	M	3,792	20,388	52,814	60,593	124,710	118,593	45,329	25,346	8,822
National	F	13,001	71,647	181,401	198,797	459,952	396,181	156,181	101,378	54,425
	M	13,814	74,975	191,120	192,301	459,772	409,181	146,578	85,156	31,884

Table 2: Age-sex breakdown of the RCGP RSC network across NHS regions

Age-Sex Profile

We work very hard to ensure that our sample population's demographics closely resemble the country as a whole. This correspondence can be seen in the age-sex profile below; the bars show the number of patients within our dataset, broken down by gender and age-band, and the lines show the distribution of England's corresponding population as a whole. The age-sex profile shows that females aged 40-65 were particularly underrepresented this season. The 0-5 age group tends to be underrepresented in most seasons as general practice registration does not generally occur until a little while after birth. Both males and females aged between 20 and 30 were slightly overrepresented this season.



Figure 1: Figure showing breakdown by age and gender within the RCGP RSC network in the reporting period of 2018-19.

Distribution of RSC Practices among NHS regions

As can be seen from the map below, practices within the Network are spread across England to reflect the distribution of the population as a whole. We vary our priorities for recruiting to try to ensure an even spread of practices.



Figure 2: Map showing the distribution of the practices within the network in 2018-19

Summary of virology and serology specimens collected:

- **Virology**

Age Band	Total	Positive for H1N1	Positive for H3N2	Positive for Flu B	Positive For Any Virus
<1	54 (2.78%)	2 (0.1%)	1 (0.1%)	0 (0%)	36 (1.9%)
01-04	218 (11.2%)	36 (1.9%)	12 (0.6%)	1(0.1%)	128 (6.6%)
05-14	197 (10.2%)	55 (2.8%)	17 (0.9%)	0 (0%)	91 (4.7 %)
15-24	175 (9%)	25 (1.3%)	13 (0.7%)	0 (0%)	51 (2.6%)
25-44	529 (27.3%)	162 (8.4%)	35 (1.8%)	0 (0%)	217 (11.2%)
45-64	468 (24.1%)	133 (6.9%)	38 (2%)	0 (0%)	215 (11.1%)
65-74	157 (8.1%)	22 (1.1%)	16 (0.8%)	0 (0%)	64 (3.3%)
75-84	120 (6.2%)	8 (0.4%)	12 (0.6%)	0 (0%)	38 (2%)
85+	22 (1.1%)	0 (0%)	0 (0%)	0 (0%)	3 (0.2%)
Total	1940 (100%)	443 (22.8%)	144 (7.4%)	1 (0.1%)	843 (43.5%)

Table 3: Table showing a breakdown of virology samples taken in the period of 2018-2019 annual report.

Virology (nasal and throat swabs) specimens were taken throughout winter. In the period of this 2018-2019 annual report, there were 1,940 virology swabs taken, summarised in Table 3.



Figure 3: This graph summarises this seasons virology sampling

In the winter of 2018-2019, Influenza A subtype H1N1pdm09 was the predominant strain followed by Influenza A (H3N2) in the latter part of the season. Very little influenza B was observed in this season.

Influenza A/H1N1 was first detected in the network in ISO week 43 (week commencing 22nd October 2018) and peaked in week 6 (week commencing 4th February 2019) (figure 3).

- **Serology**

We collected over 900 blood samples across all adult age groups for the serology pilot. Whole blood samples were received, processed to obtain sera, catalogued and stored in -80°C archive freezers within the Serum Archives section of PHEs Vaccine Evaluation Unit (VEU).



Figure 4: Graph summarising number of samples collected across different age groups for the serology pilot

Ageband	No of blood samples collected
18-29	149
30-39	156
40-49	172
50-59	167
60-69	170
70+	175
All Ages	989

Table 4: Table showing a summary of serology samples collected for the serology surveillance pilot

Vaccine Uptake

We found a good uptake of influenza vaccine in people aged 65 years and over (63%). Lower rates of immunisations were seen in at-risk patients (30%) and pregnant women (38%). Similarly, low rates of vaccine uptake were seen in children aged 2-9 (35%). There were some "other" people immunised in

primary care, who tend to be health care workers and/or carers and represented 3% of the population immunised (table 5).

GP records are of high quality for the immunisations carried out in primary care. Patients vaccinated outside of General Practice may not have information coded into their computerised medical record (CMR) system.[18]

Eligible group	Total eligible population	Vaccine coverage
All patients	3,157,894	21%
Adults aged 65+	556,444	63%
Children aged 2-9	269,261	35%
Other	1,743,391	3%
Pregnant women	32,346	38%
Risk group patients	556,452	30%

Table 5: Influenza vaccine uptake in the RCGP RSC practices 2018-2019 season

Our results showed different vaccine coverage rates than those reported by PHE. [19] However, in line with the PHE report, our results showed an increase in uptake in the older population.

This season 2018 to 2019 saw the extension of childhood vaccination programme to all those aged 9 rising to 10 years (all children aged 2-9 years at 31st August 2018 were eligible for the vaccine). [5] The phased delivery of the newly licensed adjuvant vaccine for those aged 65 and over also started. It should be noted that vaccinations administered in settings other than general practices, such as school or pharmacies, are likely to be inconsistently recorded in the general practice record. Therefore, the vaccine coverage data given here is likely to be a slight underestimate of the true rate.

Summary of vaccine effectiveness in the 2018-19 season:

The test-negative case-control (TNCC) design was used by PHE to measure vaccine effectiveness.[6] RCGP RSC data is used to calculate vaccine effectiveness (VE). Overall VE against A/H1N1 was 45.7% (95% Confidence Intervals (CI): 26.0, 60.1) and against A/H3N2 35.1% (95% CI: -3.7, 59.3). Overall, this season the VE was 44.3% (95% CI: 26.8, 57.7).

The VE for 2-17 year olds given live attenuated influenza vaccine(LAIV) was 53.0% (95% C: 8.5, 75.9) ;the VE for 18-64 year olds given any vaccine was 44.2% (95% CI: 21.3, 60.5); and for people 65 years and older VE was 49.9% (95%CI: −13.7, 77.9) and 62.0% (95% CI: 3.4, 85.0) for those who had received adjuvanted trivalent influenza vaccine (aTIV) alone.

The aTIV, introduced this season provided significant protection for persons aged 65 years and older.

Disease Incidence

We monitored 37 conditions in our weekly surveillance reports, both nationally and for the four English NHS regions, compared to our five year average. Graphs showing weekly incidence of all monitored conditions are included in Appendix A.

These graphs are presented in the same format as our weekly surveillance report. However, these graphs are based on the amalgamation of the extracts taken over the reporting period.

Like the weekly surveillance report, the data are presented in this report by disease chapter. The key points for each chapter are:

- **Water and food-borne disorders:** Presentations of intestinal infectious diseases were at or below seasonal averages except for small peaks in weeks 22 and 38. National rates of non-infective enteritis/colitis were mostly below seasonal average with a few peaks seen in midlands and east between weeks 26-30 and week 16. For both of these conditions, the incidence was higher in London than in other regions. Additionally, we saw an above seasonal average increase in intestinal infections in 0-4 year olds in the North of England. Intestinal infectious disease rates were highest in children below 4 years of age.
  Nationally, viral hepatitis was mainly below seasonal average apart from peaks in weeks 29, 33 and 13 However, seasonal incidence of viral hepatitis peaks above seasonal average were noticed across various regions throughout the season.
- **Environmentally-sensitive disorders:** Rates of asthma were mainly at the national average, apart from peaks in weeks 2 and 6, and weeks 12-15. Conjunctivitis was at below seasonal levels. Allergic rhinitis was seen as usual in weeks 24-(usual peak occurs between week 23-25) with mostly higher than the seasonal averages at the peak periods. Respiratory/chest symptoms were at or below the seasonal averages. Rate of allergic rhinitis and asthma were highest in ages 5-14 years.
- **Respiratory infections:** Nationally, most respiratory infections were at or below seasonal average except for pertussis, strep throat, infection mononucleosis influenza-like illness (ILI). ILI peaked later in the year than expected. This delay made the peak higher than the seasonal average. Incidence of common cold was consistently higher in London than other regions. The North had a higher than average incidence of acute bronchitis. Infection mononucleosis were above seasonal average for most of the season across the country. Highest rates of common cold, ILI and respiratory system diseases were seen in children under 4 years. Highest rates of bronchitis were seen in children under 4 and older adults aged 85 years and over.
- **Vaccine-sensitive disorders:** Measles, mumps and rubella all showed an above seasonal incidence
- **Skin contagions:** Bullous Dermatoses and scabies had a higher incidence than seasonally expected. Skin symptoms were above national average for the first half of the season nationally. Herpes Zoster had the lowest incidence in London, well below seasonal average.

- **Disorders affecting the nervous system.** Peripheral neuropathy rates were well below seasonal averages. Musculoskeletal symptoms, meningitis and encephalitis rates were at or below seasonal averages.
- **Genitourinary system disorders:** Presentations of urinary tract infections were slightly below seasonal average.
- **Scarlatina:** Presentations were above seasonal average for the start of the reporting season, dropping well below seasonal average from January 2019 onwards.

Disparities

We explored disparities by condition, and in comparison to the overall RSC population. The network has been previously shown to be representative of the English population.[1] We examined whether people who presented with a given condition in the previous year had different demographic characteristics (age, gender, ethnicity, deprivation, and rural, urban or conurbation living) than the general population. We have presented the distribution of these variables, with 95% confidence intervals, for each individual condition in the graphs in Appendix B.

Age

The age for each registered patient was obtained on 1st May 2019. We found the following patterns:

- Childhood conditions such as chickenpox and otitis media had a lower median than the general population.
- Common cold had a median below the population median, probably indicating a high rate of consultation in children.
- Influenza-like-illness had a similar median age as that of the general population.

Gender

Gender was recorded by the general practice on each patient's electronic record, when they first register in a practice. We found the following patterns:

- Overall more women presented with conditions than men, reflecting their higher propensity to consult.
- Women presented more often than men with asthma, hayfever, herpes simplex and urinary tract infections.
- Almost 60% of influenza-like illness consultations were for women.

Deprivation

We determined deprivation using the 2019 Index of Multiple Deprivation (IMD)[20], which assigns a score to each Lower Super Output Area (LSOA) in England.[21] When we extracted our data, each patient's postcode was converted to LSOA. A lower score represented a less deprived area. IMD was classified into five quintiles based on relative disadvantage with quintile 1 being the most deprived and 5 being the least deprived. We found that majority of the patients presenting with conditions in Appendix B had a lower median IMD score (less deprived) than the overall population

Urban, Rural or Conurbation Living

We banded together the Office of National Statistics (ONS) classifications conurbation, city or town into urban living, and rural living.[22] These were based on population density. We determined the patient's classification at individual level mapping the first four elements of the post code into conurbation, urban, or rural. These were based on the ONS lower super output area (LSOA), which has a mean size in England and Wales of 1,640, with population sizes ranging from 820 in South Cambridgeshire to 8,250 in Oxford.[23] We found that a higher percentage of population in a conurbation and urban area presented with conditions in Appendix B compared to patients in a rural area.

Episode Typing

We are committed to high data quality and encourage all member practices to record episode type. Recording episode type is the only way that we can differentiate incident (first and new) from prevalent cases (ongoing care/reviews). RCGP RSC practices get constant feedback and reminders about the importance of recording whether a clinical consultation is the first time a patient presents the condition or whether it is a follow up appointment.

We reported episode type for 6 exemplar conditions (Figure 5). For most acute conditions, episode type recording was of good quality. However, episode type recording is lacking for chronic conditions, seen here in asthma for example.



Disease	First And New (n)	Ongoing (n)	Unknown (n)	Total (n)
Allergic Rhinitis	21,076	4,918	5,145	31,139
Asthma	22,371	111,035	6,468	139,874
Bronchitis	150,825	41,066	11,191	203,082
Influenza-like illness	9,297	2,055	1,781	13,133
Intestinal Infectious Diseases	25,518	4,007	3,883	33,408
Urinary Tract Infections	47,436	17,703	4,288	69,427
Grand Total	**276,523**	**180,784**	**32,756**	**490,063**

*Data source: the RCGP RSC quarterly data feed of July 2019.

Figure 5: Recording of episode type in six exemplar conditions. Asthma (a long term condition) had poor episode typing.

Publications

Hinton W, McGovern A, Coyle R, Han TS, Sharma P, Correa A, Ferreira F, de Lusignan S. Incidence and prevalence of cardiovascular disease in English primary care: a cross-sectional and follow-up study of the Royal College of General Practitioners (RCGP) Research and Surveillance Centre (RSC). BMJ Open. 2018 Aug 20;8(8):e020282. doi: 10.1136/bmjopen-2017-020282.

de Lusignan S, Borrow R, Tripathy M, Linley E, Zambon M, Hoschler K, Ferreira F, Andrews N, Yonova I, Hriskova M, Rafi I, Pebody R. Serological surveillance of influenza in an English sentinel network: pilot study protocol. BMJ Open. 2019 Mar 8;9(3):e024285. doi: 10.1136/bmjopen-2018-024285.

Hinton W, Feher M, Munro N, Walker M, de Lusignan S. Real-world prevalence of the inclusion criteria for the LEADER trial: Data from a national general practice network. Diabetes Obes Metab. 2019 Jul;21(7):1661-1667. doi: 10.1111/dom.13710.

Hoang U, James AC, Liyanage H, Jones S, Joy M, Blair M, Rigby M, Lusignan S. Determinants of inter-practice variation in ADHD diagnosis and stimulant prescribing: cross-sectional database study of a national surveillance network. BMJ Evid Based Med. 2019 Aug;24(4):155-161. doi: 10.1136/bmjebm-2018-111133.

Coyle R, Feher M, Jones S, Hamilton M, de Lusignan S. Variation in the diagnosis and control of hypertension is not explained by conventional variables: Cross-sectional database study in English general practice. PLoS One. 2019 Jan 10;14(1):e0210657. doi: 10.1371/journal.pone.0210657.

Hinton W, Feher MD, Munro N, de Lusignan S. How Generalizable Are Cardiovascular Outcome Trials of Sodium-Glucose Co-Transporter-2 Inhibitors? A National Database Study: Study Protocol. Diabetes Ther. 2019 Jun;10(3):1163-1170. doi: 10.1007/s13300-019-0620-8.

de Lusignan S, Hinton W, Konstantara E, Munro N, Whyte M, Mount J, Feher M. Intensification to injectable therapy in type 2 diabetes: mixed methods study (protocol). BMC Health Serv Res. 2019 May 3;19(1):284. doi: 10.1186/s12913-019-4112-3.

Hinton W, Feher M, Munro N, de Lusignan S. Does Real World Use of Liraglutide Match its Use in the LEADER Cardiovascular Outcome Trial? Study Protocol. Diabetes Ther. 2018 Jun;9(3):1397-1402. doi: 10.1007/s13300-018-0390-8.

de Lusignan S, Konstantara E, Joy M, Sherlock J, Hoang U, Coyle R, Ferreira F, Jones S, O'Brien SJ. Incidence of household transmission of acute gastroenteritis (AGE) in a primary care sentinel network (1992-2017): cross-sectional and retrospective cohort study protocol. BMJ Open. 2018 Aug 23;8(8):e022524. doi: 10.1136/bmjopen-2018-022524.

Pebody RG, Sinnathamby MA, Warburton F, Andrews N, Boddington NL, Zhao H, Yonova I, Ellis J, Tessier E, Donati M, Elliot AJ, Hughes HE, Pathirannehelage S, Byford R, Smith GE, de Lusignan S, Zambon M. Uptake and impact of vaccinating primary school-age children against influenza: experiences of a live attenuated influenza vaccine programme, England, 2015/16. Euro Surveill. 2018 Jun;23(25):1700496. doi: 10.2807/1560-7917.ES.2018.23.25.1700496.

Participating Practices

This list includes all practices who were members of the RSC network at any point during the period covered by this report. For technical reasons, we were unable to extract data from all of the practices below for use in this report; therefore, the report is based on 250 of these practices. However, we would like to thank all practices for their participation in the work of the RSC.

Practice Name	**NHS Region**
ABERFELDY PRACTICE	London
ADELAIDE MEDICAL CENTRE	London
AMPTHILL PRACTICE	London
AT MEDICS	London
AT MEDICS - THE LOXFORD PRACTICE	London
BANK HOUSE SURGERY	London
BRIGSTOCK & SOUTH NORWOOD PARTNERSHIP	London
BURNLEY PRACTICE	London
CATOR MEDICAL CENTRE	London
CEDAR BROOK PRACTICE	London
CITY ROAD MEDICAL CENTRE	London
DR CURRAN & PARTNERS	London
DR KOONER AND PARTNERS	London
DR SHEILA SANTAMARIA	London
EDITH CAVELL PRACTICE	London
ELM HOUSE SURGERY	London
GLADSTONE MEDICAL CENTRE	London
HEADLEY DRIVE SURGERY	London
ILFORD MEDICAL CENTRE	London
KENTON BRIDGE MEDICAL CENTRE DR GOLDEN	London
KILLICK STREET HEALTH CENTRE	London

KINGS CROSS SURGERY	London
LAWRENCE HOUSE SURGERY	London
MILLWAY MEDICAL PRACTICE	London
MOLLISON WAY SURGERY	London
MOUNTWOOD SURGERY	London
NEW ADDINGTON GROUP PRACTICE	London
OAK LODGE MEDICAL CENTRE	London
PARKSIDE GROUP PRACTICE	London
QUEENS ROAD SURGERY	London
SILVERLOCK MEDICAL CENTRE	London
STREATHAM HIGH PRACTICE	London
STREATHAM PLACE SURGERY	London
THE ABBOTSBURY PRACTICE	London
THE BLITHEHALE MED.CTR.	London
THE DEVONSHIRE LODGE PRACTICE	London
THE EXCHANGE SURGERY	London
THE FRYENT WAY SURGERY	London
THE FULHAM MEDICAL CENTRE	London
THE GREYSWOOD PRACTICE	London
THE HAMBLEDEN CLINIC	London
THE MILL HILL SURGERY	London
THE MITCHISON ROAD SURGERY	London
THE NELSON MEDICAL PRACTICE	London
THE NEW MILL STREET SURGERY	London
THE PRACTICE ALBERT ROAD	London

THE WEMBLEY PRACTICE	London
THORNTON & VALLEY PARK SURGERY	London
TROWBRIDGE PRACTICE	London
WHITECHAPEL HEALTH CENTRE	London
WOODGRANGE MEDICAL PRACTICE	London
WOODLANDS PRACTICE	London
ALCESTER HEALTH CENTRE	Midlands And East
ALCONBURY SURGERY	Midlands And East
ARBURY MEDICAL CENTRE	Midlands And East
AUDLEY HEALTH CENTRE	Midlands And East
BASLOW HEALTH CENTRE	Midlands And East
BLOXWICH MEDICAL PRACTICE	Midlands And East
BRETTON MEDICAL PRACTICE	Midlands And East
BUDBROOKE MEDICAL CENTRE	Midlands And East
BUSHLOE SURGERY	Midlands And East
CASTLEGATE SURGERY	Midlands And East
CHERRY HINTON MEDICAL CENTRE	Midlands And East
CHILWELL VALLEY AND MEADOWS PRACTICE	Midlands And East
COLLINGHAM MEDICAL CENTRE	Midlands And East
COMBERTON SURGERY	Midlands And East
CORBETT MEDICAL PRACTICE	Midlands And East
COTTERILS LANE SURGERY	Midlands And East
COVENTRY ROAD PRACTICE	Midlands And East
CREFFIELD MEDICAL GROUP	Midlands And East
DR MK LAKHANI'S PRACTICE	Midlands And East

DRONFIELD MEDICAL PRACTICE	Midlands And East
EAST PARK MEDICAL PRACTICE	Midlands And East
EVE HILL MEDICAL PRACTICE	Midlands And East
FAIRFIELDS PRACTICE	Midlands And East
FRAMLINGHAM SURGERY	Midlands And East
FRANKLEY HEALTH CENTRE	Midlands And East
GARSTON MEDICAL CENTRE	Midlands And East
GREAT BENTLEY SURGERY	Midlands And East
HARBORNE MEDICAL PRACTICE	Midlands And East
HARVEY GROUP PRACTICE	Midlands And East
HIGHLANDS SURGERY	Midlands And East
HUSBANDS BOSWORTH MEDICAL CENTRE	Midlands And East
KEYNELL COVERT	Midlands And East
KNOCKIN MEDICAL CENTRE	Midlands And East
LAKESIDE HEALTHCARE STAMFORD	Midlands And East
LEEK HEALTH CENTRE	Midlands And East
MARKET HARBOROUGH MED.CTR	Midlands And East
MONKSPATH SURGERY	Midlands And East
MUCH WENLOCK & CRESSAGE MEDICAL PRACTICE	Midlands And East
NEW ROAD SURGERY BROMSGROVE	Midlands And East
PAPWORTH SURGERY	Midlands And East
PARK LEYS MEDICAL PRACTICE	Midlands And East
PONTESBURY MEDICAL PRAC	Midlands And East
PRIMROSE LANE PRACTICE	Midlands And East
REVEL SURGERY	Midlands And East

SHERBOURNE MEDICAL CENTRE	Midlands And East
SHIPSTON MEDICAL CENTRE	Midlands And East
STATION VIEW HEALTH CENTRE	Midlands And East
STIRCHLEY MEDICAL PRACTICE	Midlands And East
STOCKINGFORD MEDICAL CENTRE	Midlands And East
THE ATHERSTONE SURGERY	Midlands And East
THE CALVERTON PRACTICE	Midlands And East
THE GRANGE MEDICAL CENTRE	Midlands And East
THE SURGERY @ AYLESTONE	Midlands And East
VALE OF RED HORSE	Midlands And East
VICTORIA ROAD SURGERY	Midlands And East
WANSFORD	Midlands And East
WELLBROOK MEDICAL CENTRE	Midlands And East
WELLSIDE SURGERY	Midlands And East
WOLSTANTON MEDICAL CENTRE	Midlands And East
108 RAWLING ROAD(RAWLING ROAD PRACTICE)	North
AMBLESIDE HEALTH CENTRE	North
AMPLEFORTH SURGERY	North
ASH TREE HOUSE SURGERY	North
ASHCROFT SURGERY	North
ASPATRIA MEDICAL GROUP	North
BARLOW MEDICAL CENTRE	North
BARNOLDSWICK MED CTR	North
BARRINGTON MEDICAL CENTRE	North
BEACON VIEW MEDICAL CENTRE	North

BELLBROOKE SURGERY	North
BELLE VALE HEALTH CENTRE	North
BERRY LANE MEDICAL CENTRE	North
BLOCK LANE SURGERY	North
BRIDGE END SURGERY	North
BROWNLOW GROUP PRACTICE	North
BURN BRAE MEDICAL GROUP	North
CARTMEL SURGERY	North
CASTLEFIELDS HEALTH CENTRE	North
CHADDERTON SOUTH HEALTH CENTRE	North
CHEVELEY PARK MEDICAL CTR	North
CLEVELEYS GROUP PRACTICE	North
CLIFTON MEDICAL CENTRE	North
CONISBROUGH GROUP PRACTICE	North
COURT THORN SURGERY	North
DARWEN HEALTHCARE	North
EASTHAM GROUP PRACTICE	North
ELLENBROOK MEDICAL CENTRE	North
FELL TOWER MEDICAL CENTRE	North
GARSWOOD SURGERY	North
GLENPARK MEDICAL CENTRE	North
GREENHEAD FAMILY DOCTORS	North
GROVE HOUSE PRACTICE	North
GUIDEPOST MEDICAL GROUP	North
HAIGH HALL MEDICAL PRACTICE	North

HAYDOCK MEDICAL CENTRE	North
HEDON GROUP PRACTICE	North
HELSBY HEALTH CENTRE	North
HOLLYHURST MEDICAL CENTRE	North
IMEARY STREET PRACTICE	North
IRELAND WOOD SURGERY	North
JAMES STREET GROUP PRACT	North
LACHE HEALTH CENTRE	North
LAUREL BANK SURGERY	North
LAUREL BANK SURGERY	North
MANCHESTER MEDICAL	North
MEREPARK MEDICAL CENTRE	North
MIDDLEWOOD PARTNERSHIP	North
MY HEALTH GROUP	North
NORMANBY MEDICAL CENTRE	North
NORTH STREET MEDICAL PRACTICE	North
OAK VALE MEDICAL CENTRE	North
OAKENHURST MEDICAL PRACTICE	North
ORCHARD SURGERY	North
PARK VIEW MEDICAL CENTRE	North
PENDLE VIEW MEDICAL CTRE	North
PICKERING MEDICAL PRACTICE	North
PRIORY MEDICAL CENTRE	North
QUEENS ROAD SURGERY	North
REGENT HOUSE SURGERY	North

REGENT MEDICAL CENTRE	North
RIVERSIDE SURGERY	North
RUSTLINGS ROAD MEDICAL CENTRE	North
SADDLEWORTH MEDICAL PRACTICE	North
SANDY LANE SURGERY	North
SCORTON MEDICAL CENTRE	North
SEDBERGH MEDICAL PRACTICE	North
SHIFA SURGERY	North
SLOAN MEDICAL CENTRE	North
ST CATHERINE'S SURGERY	North
ST FILLAN'S MEDICAL CTRE	North
ST GABRIEL'S MEDICAL CENTRE	North
ST PAULS MEDICAL CENTRE	North
ST. JAMES' HEALTH CENTRE	North
STATION HOUSE SURGERY	North
STOCKWELL ROAD SURGERY	North
STONELEIGH SURGERY	North
TEAMS MEDICAL PRACTICE	North
THE ADDERLANE SURGERY	North
THE GILL MEDICAL PRACTICE	North
THE HAVEN SURGERY	North
THE KILTEARN MEDICAL CTR.	North
THE MARSHSIDE SURGERY	North
THE MEDICAL CENTRE DR OKORIE	North
THE RICHMOND HILL PRACTICE	North

THE SCHOOLHOUSE SURGERY	North
THE VILLAGE SURGERIES CROSTON&ECCLESTON	North
THORNBURY MEDICAL PRACTICE	North
THORNTON & DENHOLME MEDICAL PRACTICE	North
VAUXHALL HEALTH CENTRE	North
VILLA MED CTR	North
WEST COMMON LANE TEACHING PRACTICE	North
WEST TIMPERLEY MEDICAL CENTRE	North
WESTCLIFFE MEDICAL CENTRE	North
WHALLEY MEDICAL CENTRE	North
WHITE ROSE SURGERY	North
WINDERMERE HEALTH CENTRE	North
WOOLTON HOUSE MEDICAL CTR	North
WORDEN MEDICAL CENTRE	North
19 BEAUMONT STREET SURGERY	South
ASHLEY CENTRE SURGERY	South
AVISFORD MEDICAL GROUP	South
AXBRIDGE SURGERY	South
BEACONSFIELD MEDICAL PRACTICE	South
BEECHWOOD MEDICAL PRACTICE	South
BERINSFIELD HEALTH CENTRE	South
BRIDGE PRACTICE	South
BROADSHIRES HEALTH CENTRE	South
BURMA HILL PRACTICE	South
BUTTERCROSS HEALTH CENTRE	South

CAEN MEDICAL CENTRE	South
CANTERBURY MEDICAL PRACTICE	South
CAPELFIELD SURGERY	South
CARNEWATER PRACTICE	South
CHEDDAR MEDICAL CENTRE	South
CHERTSEY HEALTH CENTRE	South
CLEVEDON MEDICAL CENTRE	South
COMPASS HOUSE MEDICAL CENTRES	South
CONCORD MEDICAL CENTRE	South
CORNER PLACE SURGERY	South
CREWKERNE HEALTH CENTRE, CREWKERNE	South
DOWNS WAY MEDICAL PRACTICE	South
EAST QUAY MEDICAL CENTRE	South
FOUNTAIN PRACTICE	South
FRIARSGATE PRACTICE	South
FURNACE GREEN SURGERY	South
GILLINGHAM MEDICAL PRACTICE	South
GOSPORT MEDICAL CENTRE	South
GREENWAY COMMUNITY PRACTICE	South
GROVE HOUSE SURGERY	South
GUILDOWNS GROUP PRACTICE	South
HARBOUR VIEW HEALTHCARE	South
HARPTREE SURGERY	South
HASLEMERE HEALTH CENTRE	South
HEATHERSIDE SURGERY	South

HENFIELD MEDICAL CENTRE	South
HIGHCLIFFE MEDICAL CENTRE	South
IRNHAM LODGE SURGERY	South
LANGPORT SURGERY	South
LIPHOOK AND LISS SURGERY	South
LOWFIELD MEDICAL CENTRE	South
MENDIP VALE MEDICAL PRACTICE	South
MILLBROOK SURGERY, CASTLE CARY	South
MILMAN ROAD SURGERY	South
MONKS PARK SURGERY	South
NEW HAYESBANK SURGERY	South
NEW INN SURGERY	South
NEWTON PLACE SURGERY	South
NIGHTINGALE VALLEY PRACTICE	South
NORTH ROAD WEST MED.CTR.	South
NORTHBOURNE MEDICAL CENTRE	South
OAKFIELD SURGERY	South
OAKLANDS HEALTH CENTRE	South
PARK ROAD GROUP PRACTICE	South
PARK SURGERY	South
PHOENIX HEALTH GROUP	South
PHOENIX SURGERY	South
PORT VIEW SURGERY	South
PORTISHEAD MEDICAL GROUP	South
PORTSLADE HEALTH CENTRE	South

RINGMEAD MEDICAL PRACTICE	South
SPRING STREET SURGERY	South
STEYNING HEALTH CENTRE	South
STOCKBRIDGE SURGERY	South
STONELEIGH SURGERY	South
SUMMERTOWN HEALTH CENTRE	South
TAWSTOCK MEDICAL CENTRE, CHARD	South
THE ANDOVER HEALTH CENTRE MEDICAL PRACT	South
THE CAMBRIDGE PRACTICE	South
THE CHURCH VIEW PRACTICE	South
THE GRANGE PRACTICE	South
THE HALL PRACTICE	South
THORNDIKE PARTNERSHIP	South
TORRINGTON HEALTH CENTRE	South
TYNTESFIELD MEDICAL GROUP	South
UNITY HEALTH	South
VICTORIA PRACTICE	South
VINE MEDICAL GROUP	South
WADEBRIDGE & CAMEL ESTUARY PRACTICE	South
WARDERS MEDICAL CENTRE	South
WARLINGHAM GREEN MED PRAC	South
WELLS HEALTH CENTRE	South
WEST COKER SURGERY	South
WESTBURY ON TRYM PRIMARY CARE CENTRE	South
WESTONGROVE PARTNERSHIP	South

WHIPTON SURGERY	South
WHITELADIES MEDICAL GROUP	South
WINCANTON HEALTH CENTRE	South
WOKINGHAM MEDICAL CENTRE	South
WONFORD GREEN SURGERY	South
WOODBRIDGE HILL SURGERY	South
YORKLEIGH SURGERY(CT)	South

Acknowledgements

All the practices and their patients within our network. Without the support of our member practices EMIS, TPP, InPractice Systems, and Wellbeing software for facilitating our pseudonymised data extraction.

Public Health England colleagues at Colindale and Manchester laboratories.

Contributors

Simon de Lusignan

Manasa Tripathy

Rachel Byford

Julian Sherlock

Cecilia Okusi

References

[1] de Lusignan S, Correa A, Smith GE, Yonova I, Pebody R, Ferreira F, Elliot AJ, Fleming D. RCGP Research and Surveillance Centre: 50 years' surveillance of influenza, infections, and respiratory conditions. Br J Gen Pract. 2017 Oct;67(663):440-441. doi: 10.3399/bjgp17X692645.

[2] de Lusignan S. Codes, classifications, terminologies and nomenclatures: definition, development and application in practice. Inform Prim Care. 2005;13(1):65-70. doi: 10.14236/jhi.v13i1.580.

[3] Morbey RA, Elliot AJ, Harcourt S, Smith S, de Lusignan S, Pebody R, Yeates A, Zambon M, Smith GE. Estimating the burden on general practitioner services in England from increases in respiratory disease associated with seasonal respiratory pathogen activity. Epidemiol Infect. 2018 Aug;146(11):1389-1396. doi: 10.1017/S0950268818000262.

[4] Broberg EK, Waris M, Johansen K, Snacken R, Penttinen P; European Influenza Surveillance Network. Seasonality and geographical spread of respiratory syncytial virus epidemics in 15 European countries, 2010 to 2016. Euro Surveill. 2018 Feb;23(5):17-00284. doi: 10.2807/1560-7917.ES.2018.23.5.17-00284.
.

[5] Birrell PJ, Zhang XS, Corbella A, van Leeuwen E, Panagiotopoulos N, Hoschler K, Elliot AJ, McGee M, Lusignan S, Presanis AM, Baguelin M, Zambon M, Charlett A, Pebody RG, Angelis D. Forecasting the 2017/2018 seasonal influenza epidemic in England using multiple dynamic transmission models: a case study. BMC Public Health. 2020 Apr 15;20(1):486. doi: 10.1186/s12889-020-8455-9.

[6] Metcalf CJ, Farrar J, Cutts FT, Basta NE, Graham AL, Lessler J, Ferguson NM, Burke DS, Grenfell BT. Use of serological surveys to generate key insights into the changing global landscape of infectious disease. Lancet. 2016 Aug 13;388(10045):728-30. doi: 10.1016/S0140-6736(16)30164-7.

[7] de Lusignan S, Correa A. Opportunities and challenges of a World Serum Bank. Lancet. 2017 Jan 21;389(10066):250-251. doi: 10.1016/S0140-6736(17)30046-6.

[8] de Lusignan S, Borrow R, Tripathy M, Linley E, Zambon M, Hoschler K, Ferreira F, Andrews N, Yonova I, Hriskova M, Rafi I, Pebody R. Serological surveillance of influenza in an English sentinel network: pilot study protocol. BMJ Open. 2019 Mar 8;9(3):e024285. doi: 10.1136/bmjopen-2018-024285.

[9] Pathirannehelage S, Kumarapeli P, Byford R, Yonova I, Ferreira F, de Lusignan S. Uptake of a Dashboard Designed to Give Realtime Feedback to a Sentinel Network About Key Data Required for Influenza Vaccine Effectiveness Studies. Stud Health Technol Inform. 2018;247:161-165.

[10] Pebody RG, Whitaker H, Ellis J, Andrews N, Marques DFP, Cottrell S, Reynolds AJ, Gunson R, Thompson C, Galiano M, Lackenby A, Robertson C, O'Doherty MG, Owens K, Yonova I, Shepherd SJ, Moore C, Johnston J, Donati M, McMenamin J, Lusignan S, Zambon M. End of season influenza vaccine effectiveness in primary care in adults and children in the United Kingdom in 2018/19. Vaccine. 2020 Jan 16;38(3):489-497. doi: 10.1016/j.vaccine.2019.10.071.

[11] Kissling E, Rose A, Emborg HD, Gherasim A, Pebody R, Pozo F, Trebbien R, Mazagatos C, Whitaker H, Valenciano M; European Ive Group. Interim 2018/19 influenza vaccine effectiveness: six European studies, October 2018 to January 2019. Euro Surveill. 2019 Feb;24(8):1900121. doi: 10.2807/1560-7917.ES.2019.24.1900121.

[12] Taylor MJ. Legal bases for disclosing confidential patient information for public health: distinguishing between health protection and health improvement. Medical Law Review. Summer 2015:23(3);348–374. https://doi.org/10.1093/medlaw/fwv018

[13] Useful introduction to measuring VE: A useful introduction is at: https://www.who.int/immunization/research/meetings_workshops/5_Nick_Andrews_VE_uk.pdf

[14] Pebody RG, Green HK, Andrews N, Zhao H, Boddington N, Bawa Z, Durnall H, Singh N, Sunderland A, Letley L, Ellis J, Elliot AJ, Donati M, Smith GE, de Lusignan S, Zambon M. Uptake and impact of a new live attenuated influenza vaccine programme in England: early results of a pilot in primary school-age children, 2013/14 influenza season. Euro Surveill. 2014 Jun 5;19(22):20823. doi: 10.2807/1560-7917.es2014.19.22.20823..

[15] de Lusignan S, Correa A, Pathirannehelage S, Byford R, Yonova I, Elliot AJ, Lamagni T, Amirthalingam G, Pebody R, Smith G, Jones S, Rafi I. RCGP Research and Surveillance Centre Annual Report 2014-2015: disparities in presentations to primary care. Br J Gen Pract. 2017 Jan;67(654):e29-e40. doi: 10.3399/bjgp16X688573. Erratum in: Br J Gen Pract. 2019 Mar;69(680):120.

[16] McGovern A, Hinton W, Correa A, Munro N, Whyte M, de Lusignan S. Real-world evidence studies into treatment adherence, thresholds for intervention and disparities in treatment in people with type 2 diabetes in the UK. BMJ Open. 2016 Nov 24;6(11):e012801. doi: 10.1136/bmjopen-2016-012801.
.

[17] Mold F, Raleigh M, Alharbi NS, de Lusignan S. The Impact of Patient Online Access to Computerized Medical Records and Services on Type 2 Diabetes: Systematic Review. J Med Internet Res. 2018 Jul 6;20(7):e235. doi: 10.2196/jmir.7858.

[18] de Lusignan S , Hoghton M , Rafi I . Flu vaccination by pharmacists leads to suboptimal medical records. BMJ 2017;359:j5084.doi:10.1136/bmj.j5084

[19] Public Health England Seasonal influenza vaccine uptake in GP patients: winter season 2018 to 2019. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/804889/Seasonal_influenza_vaccine_uptake_in_GP_patients_1819.pdf

[20] Department for Communities and Local Government (2015). The English Indices of Deprivation 2015. Available at: https://www.gov.uk/government/statistics/english-indices-of-deprivation-2015

[21] Office of National Statistics (2011). Postcodes (Enumeration) to output areas to lower layer SOA to middle layer SOA to local authority districts E+W lookup. Available at: https://geoportal.statistics.gov.uk/Docs/Lookups/Postcodes_(Enumeration)_(2011)_to_output_areas_(2011)_to_lower_layer_SOA_(2011)_to_middle_layer_SOA_(2011)_to_local_authority_districts_(2011)_E+W_lookup.zip

[22] ONS Guide to applying the Rural Urban Classification to data https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/539241/Guide_to_applying_the_rural_urban_classification_to_data.pdf

[23] English LSOA Rural/Urban Classification, 2011 https://borders.ukdataservice.ac.uk/easy_download_data.html?data=England_lsoa_ru_classn_2011

APPENDIX A : Weekly Disease Incidence Graphs

1. Water and Food Borne Disorders:








National
North
South
London
Midlands And East
5yr Avg
Viral Hepatitis (ICD10 : B15-B19)
Rate per 100,000
2.0
1.6
1.2
0.8
0.4
0.0
ISOWeek No

2. Environmentally Sensitive Disorders:








National
North
South
London
Midlands And East
5yr Avg
Respiratory / chest symptoms (ICD10 : R05 - R07; R09)
Rate per 100,000
600
500
400
300
200
100
0
19 21 23 25 27 29 31 33 35 37 39 41 43 45 47 49 51 1 3 5 7 9 11 13 15 17
ISOWeek No

3. Respiratory Infections:









Pleurisy (ICD10 : R091)




National
North
South
London
Midlands And East
5yr Avg
Respiratory disorders (ICD10 : J00-J99)
Rate per 100,000
600
500
400
300
200
100
0
19 21 23 25 27 29 31 33 35 37 39 41 43 45 47 49 51 1 3 5 7 9 11 13 15 17
ISOWeek No


Acute Sinusitis (ICD10 : J01)
Rate per 100,000
50
40
30
20
10
0
ISOWeek No


Strep throat / peritonsillar abscess (ICD10 : A38; J020; J36)
Rate per 100,000
6
5
4
3
2
1
0
ISOWeek No


National
North
South
London
Midlands And East
5yr Avg
Tonsilitis / Pharyngitis (ICD10 : J02 - J03)
Rate per 100,000
0
20
40
60
80
19 21 23 25 27 29 31 33 35 37 39 41 43 45 47 49 51 1 3 5 7 9 11 13 15 17
ISOWeek No


Upper Respiratory Tract Infections (ICD10 : J00 - J06)
Rate per 100,000
0
100
200
300
400
19 21 23 25 27 29 31 33 35 37 39 41 43 45 47 49 51 1 3 5 7 9 11 13 15 17
ISOWeek No


Pertussis (ICD10 : A37)
Rate per 100,000
0.0
0.4
0.8
1.2
1.6
19 21 23 25 27 29 31 33 35 37 39 41 43 45 47 49 51 1 3 5 7 9 11 13 15 17
ISOWeek No


National
North
South
London
Midlands And East
5yr Avg
Infectious Mononucleosis (ICD10 : B27)
Rate per 100,000
2.0
1.5
1.0
0.5
0.0
19 21 23 25 27 29 31 33 35 37 39 41 43 45 47 49 51 1 3 5 7 9 11 13 15 17
ISOWeek No


Lower Respiratory Tract Infections (ICD10 : J20-J22)
Rate per 100,000
200
150
100
50
0
ISOWeek No


Acute Otitis Media (ICD10 : H650 - H651; H660; H669)
Rate per 100,000
50
40
30
20
10
0
19 21 23 25 27 29 31 33 35 37 39 41 43 45 47 49 51 1 3 5 7 9 11 13 15 17
ISOWeek No

4. Vaccine Sensitive Disorders:



5. Skin Contagions:








National
North
South
London
Midlands And East
5yr Avg
Herpes Zoster (ICD10 : B02)
Rate per 100,000
0
4
8
12
16
19 21 23 25 27 29 31 33 35 37 39 41 43 45 47 49 51 1 3 5 7 9 11 13 15 17
ISOWeek No


Skin / subcutaneous infections (ICD10 : L00 - L08)
Rate per 100,000
0
25
50
75
100
19 21 23 25 27 29 31 33 35 37 39 41 43 45 47 49 51 1 3 5 7 9 11 13 15 17
ISOWeek No


Scabies (ICD10 : B86)
Rate per 100,000
0
2
4
6
8
19 21 23 25 27 29 31 33 35 37 39 41 43 45 47 49 51 1 3 5 7 9 11 13 15 17
ISOWeek No


National
North
South
London
Midlands And East
5yr Avg
Skin symptoms (ICD10 : R20 - R23)
Rate per 100,000
0
15
30
45
60
19 21 23 25 27 29 31 33 35 37 39 41 43 45 47 49 51 1 3 5 7 9 11 13 15 17
ISOWeek No


Impetigo (ICD10 - L01)
Rate per 100,000
0
4
8
12
16
19 21 23 25 27 29 31 33 35 37 39 41 43 45 47 49 51 1 3 5 7 9 11 13 15 17
ISOWeek No

6. Disorders Affecting the Nervous System:







7. Genitourinary System Disorders:



Incidence of Scarlatina




Weekly disease incidence by age group
<1yr
1-4yrs
5-14yrs
15-24yrs
25-44yrs
45-64yrs
65-74yrs
75-84yrs
85+yrs
All Ages
Allergic Rhinitis
Asthma
Bronchitis
Rate per 100,000
0
50
100
150
200
10
20
30
40
200
400
600
800
1000
19 21 23 25 27 29 31 33 35 37 39 41 43 45 47 49 51 1 3 5 7 9 11 13 15 17


<1yr
1-4yrs
5-14yrs
15-24yrs
25-44yrs
45-64yrs
65-74yrs
75-84yrs
85+yrs
All Ages
Common Cold
Rate per 100,000
1750
1500
1250
1000
750
500
250
0
19 21 23 25 27 29 31 33 35 37 39 41 43 45 47 49 51 1 3 5 7 9 11 13 15 17
Intestinal Infectious Diseases
Rate per 100,000
150
125
100
75
50
25
0
19 21 23 25 27 29 31 33 35 37 39 41 43 45 47 49 51 1 3 5 7 9 11 13 15 17
Influenza-like illness
Rate per 100,000
35
30
25
20
15
10
5
0
19 21 23 25 27 29 31 33 35 37 39 41 43 45 47 49 51 1 3 5 7 9 11 13 15 17


<1yr
1-4yrs
5-14yrs
15-24yrs
25-44yrs
45-64yrs
65-74yrs
75-84yrs
85+yrs
All Ages
Respiratory System Diseases
Rate per 100,000
3000
2500
2000
1500
1000
500
0
19 21 23 25 27 29 31 33 35 37 39 41 43 45 47 49 51 1 3 5 7 9 11 13 15 17

APPENDIX B: Demographic distribution by condition
1. Water and Food Borne Disorders:

Intestinal Infections (ICD10 : A00-A09)

Age-sex profile



Age Band	Condition Female Rate	Condition Male Rate	Condition Female Population	Condition Male Population
<1yr	2.09	2.83	105	125
1-4yrs	18.82	23.70	947	1,046
5-14yrs	14.19	18.24	714	805
15-24yrs	9.16	7.95	461	351
25-44yrs	23.79	19.42	1,197	857
45-64yrs	16.64	16.50	837	728
65-74yrs	7.14	5.94	359	262
75-84yrs	5.47	3.81	275	168
85+yrs	2.70	1.61	136	71

Index of Multiple Deprivation (IMD)



Ethnic group



Conurbation, Urban and Rural Living



Non-infective Enteritis / Colitis (ICD10 : K50-K52)

Age-sex profile



Age Band	Condition Female Rate	Condition Male Rate	Condition Female Population	Condition Male Population
<1yr	2.50	3.47	121	145
1-4yrs	14.55	18.99	705	794
5-14yrs	10.87	15.47	527	647
15-24yrs	10.71	10.50	519	439
25-44yrs	25.46	22.64	1,234	947
45-64yrs	17.62	16.07	854	672
65-74yrs	8.52	6.05	413	253
75-84yrs	5.92	5.05	287	211
85+yrs	3.86	1.77	187	74

Index of Multiple Deprivation (IMD)



Ethnic group



Conurbation, Urban and Rural Living



Viral Hepatitis (ICD10 : B15-B19)

Age-sex profile



Age Band	Condition Female Rate	Condition Male Rate	Condition Female Population	Condition Male Population
<1yr	0.00	0.00	0.00	0.00
1-4yrs	0.00	0.00	0.00	0.00
5-14yrs	0.00	1.89	0.00	3.00
15-24yrs	6.73	4.40	7.00	7.00
25-44yrs	43.27	45.91	45.00	73.00
45-64yrs	35.58	38.36	37.00	61.00
65-74yrs	11.54	7.55	12.00	12.00
75-84yrs	2.88	1.89	3.00	3.00
85+yrs	0.00	0.00	0.00	0.00

Index of Multiple Deprivation (IMD)



Ethnic group



Conurbation, Urban and Rural Living



2. Environmentally Sensitive Disorders:

Asthma (ICD10 : J45 - J46)

Age-sex profile



Age Band	Condition Female Rate	Condition Male Rate	Condition Female Population	Condition Male Population
<1yr	0.00	0.00	0	0
1-4yrs	2.31	5.24	200	311
5-14yrs	10.73	21.44	927	1,272
15-24yrs	10.81	9.83	934	583
25-44yrs	26.92	23.30	2,327	1,382
45-64yrs	29.80	26.05	2,576	1,545
65-74yrs	10.81	8.41	934	499
75-84yrs	6.58	4.45	569	264
85+yrs	2.04	1.28	176	76

Index of Multiple Deprivation (IMD)



Ethnic group



Conurbation, Urban and Rural Living



Conjunctivitis (ICD10 : H10 - H13)

Age-sex profile



Age Band	Condition Female Rate	Condition Male Rate	Condition Female Population	Condition Male Population
<1yr	6.03	7.91	765	849
1-4yrs	24.11	32.81	3,059	3,520
5-14yrs	8.32	11.51	1,056	1,235
15-24yrs	5.05	3.97	641	426
25-44yrs	14.64	10.19	1,858	1,093
45-64yrs	16.92	13.31	2,147	1,428
65-74yrs	9.77	8.69	1,240	932
75-84yrs	8.08	7.22	1,025	775
85+yrs	7.06	4.38	896	470

Index of Multiple Deprivation (IMD)



Ethnic group



Conurbation, Urban and Rural Living



Hayfever/Allergic Rhinitis (ICD10: J30)

Age-sex profile



Age Band	Condition Female Rate	Condition Male Rate	Condition Female Population	Condition Male Population
<1yr	0.06	0.10	4	6
1-4yrs	2.41	4.43	168	268
5-14yrs	14.70	28.06	1,026	1,697
15-24yrs	16.59	16.80	1,158	1,016
25-44yrs	36.35	25.75	2,537	1,557
45-64yrs	18.77	15.38	1,310	930
65-74yrs	6.35	5.34	443	323
75-84yrs	3.50	3.09	244	187
85+yrs	1.28	1.04	89	63

Index of Multiple Deprivation (IMD)



Ethnic group



Conurbation, Urban and Rural Living



Respiratory / chest symptoms (ICD10 : R05 - R07; R09)

Age-sex profile



Age Band	Condition Female Rate	Condition Male Rate	Condition Female Population	Condition Male Population
<1yr	0.51	1.07	50	93
1-4yrs	3.59	5.13	354	446
5-14yrs	5.59	6.50	551	565
15-24yrs	8.57	7.96	844	692
25-44yrs	24.40	24.09	2,404	2,093
45-64yrs	29.45	28.93	2,901	2,514
65-74yrs	13.12	12.80	1,292	1,112
75-84yrs	9.36	9.30	922	808
85+yrs	5.41	4.21	533	366

Index of Multiple Deprivation (IMD)



Ethnic group



Conurbation, Urban and Rural Living



3. Respiratory Infections:

Bronchitis (ICD10: J20-J21,J40)

Age-sex profile



Age Band	Condition Female Rate	Condition Male Rate	Condition Female Population	Condition Male Population
<1yr	1.41	2.90	508	802
1-4yrs	8.07	12.88	2,916	3,565
5-14yrs	3.51	5.23	1,268	1,449
15-24yrs	3.90	3.61	1,410	1,000
25-44yrs	17.16	13.46	6,199	3,726
45-64yrs	26.68	24.56	9,634	6,800
65-74yrs	14.93	15.60	5,393	4,318
75-84yrs	13.26	13.86	4,789	3,836
85+yrs	11.07	7.90	3,998	2,187

Index of Multiple Deprivation (IMD)



Ethnic group



Conurbation, Urban and Rural Living



Common Cold (ICD10 : R05 - R07; R09)

Age-sex profile



Age Band	Condition Female Rate	Condition Male Rate	Condition Female Population	Condition Male Population
<1yr	4.07	6.27	1,798	2,103
1-4yrs	24.79	34.62	10,961	11,618
5-14yrs	13.51	17.69	5,975	5,936
15-24yrs	8.54	6.50	3,775	2,183
25-44yrs	21.11	12.93	9,336	4,339
45-64yrs	16.60	11.97	7,341	4,017
65-74yrs	5.74	5.36	2,537	1,798
75-84yrs	3.68	3.29	1,626	1,105
85+yrs	1.97	1.38	869	464

Index of Multiple Deprivation (IMD)



Ethnic group



Conurbation, Urban and Rural Living



Influenza-like illness (ICD10 : J09 - J11)

Age-sex profile



Age Band	Condition Female Rate	Condition Male Rate	Condition Female Population	Condition Male Population
<1yr	0.19	0.30	8	9
1-4yrs	2.94	5.28	125	158
5-14yrs	5.66	7.88	241	236
15-24yrs	9.75	10.86	415	325
25-44yrs	35.91	33.23	1,529	995
45-64yrs	33.16	30.26	1,412	906
65-74yrs	7.21	7.38	307	221
75-84yrs	3.92	3.74	167	112
85+yrs	1.27	1.07	54	32

Index of Multiple Deprivation (IMD)



Ethnic group



Conurbation, Urban and Rural Living



Laryngitis / Tracheitis (ICD10 : J04)

Age-sex profile



Age Band	Condition Female Rate	Condition Male Rate	Condition Female Population	Condition Male Population
<1yr	0.00	0.00	0.0	0.0
1-4yrs	0.65	0.40	2.0	1.0
5-14yrs	6.21	6.32	19.0	16.0
15-24yrs	70.92	69.17	217.0	175.0
25-44yrs	18.63	21.74	57.0	55.0
45-64yrs	2.94	1.98	9.0	5.0
65-74yrs	0.33	0.40	1.0	1.0
75-84yrs	0.33	0.00	1.0	0.0
85+yrs	0.00	0.00	0.0	0.0

Index of Multiple Deprivation (IMD)



Ethnic group



Conurbation, Urban and Rural Living



Pleurisy (ICD10 : R091)

Age-sex profile



Age Band	Condition Female Rate	Condition Male Rate	Condition Female Population	Condition Male Population
<1yr	0.00	0.00	0.0	0.0
1-4yrs	0.00	0.34	0.0	2.0
5-14yrs	0.53	1.18	3.0	7.0
15-24yrs	2.85	1.18	16.0	7.0
25-44yrs	19.04	9.27	107.0	55.0
45-64yrs	30.96	21.25	174.0	126.0
65-74yrs	18.68	24.28	105.0	144.0
75-84yrs	14.41	30.69	81.0	182.0
85+yrs	13.52	11.80	76.0	70.0

Index of Multiple Deprivation (IMD)



Ethnic group



Conurbation, Urban and Rural Living



Mean weekly incidence rate per 100,000 Persons.

Chickenpox (ICD10: B01)

		M										F									
		<1yr	1-4yrs	5-14yrs	15-24yrs	25-44yrs	45-64yrs	65-74yrs	75-84yrs	85+yrs	All Ages	<1yr	1-4yrs	5-14yrs	15-24yrs	25-44yrs	45-64yrs	65-74yrs	75-84yrs	85+yrs	All Ages
4 weekly	1	0	109	38	2	1	1	0	0	0	10	0	105	39	3	3	0	1	0	0	10
	2	0	63	27	3	2	0	0	0	0	7	0	71	22	3	1	1	0	0	0	6
	3	0	45	22	0	0	0	0	0	0	5	0	57	19	0	1	0	0	0	0	5
	4	0	35	7	0	0	0	0	0	1	3	0	28	9	0	1	0	0	0	0	3
	5	0	26	5	0	0	0	0	0	0	2	0	25	5	1	1	0	0	0	0	2
	6	28	41	11	0	1	0	0	0	0	4	9	55	8	1	1	1	0	0	0	4
	7	36	62	15	1	1	0	0	0	0	5	6	48	15	1	1	0	0	0	0	4
	8	18	56	15	1	1	0	0	0	0	5	13	54	17	1	1	0	0	0	0	5
	9	51	65	16	1	1	0	0	0	0	6	33	52	17	1	0	0	0	0	0	5
	10	36	59	13	1	1	0	0	0	0	5	13	57	12	2	1	0	0	0	0	5
	11	42	82	23	1	1	1	0	0	0	8	50	83	23	1	1	0	0	0	0	7
	12	70	101	27	1	1	0	0	0	0	9	56	73	25	2	1	0	0	0	0	7
	13	78	78	18	2	1	0	0	1	0	7	76	85	17	3	1	0	0	0	1	7
Quarter	1	0	72	28	1	1	0	0	0	0	7	0	77	27	2	1	0	0	0	0	7
	2	16	38	8	0	1	0	0	0	0	3	3	38	8	1	1	0	0	0	0	3
	3	32	61	15	1	1	0	0	0	0	5	19	53	15	1	1	0	0	0	0	5
	4	62	84	22	1	1	0	0	0	0	8	57	79	21	2	1	0	0	0	0	7
Year	18/19	111	1,584	1,147	73	130	44	1	2	1	3,093	82	1,445	1,072	90	163	43	8	0	1	2,904
Episodes	F/N	27	64	19	1	1	0	0	0	0	6	19	62	18	1	1	0	0	0	0	5

Mean weekly incidence rate per 100,000 Persons.

Chickenpox (ICD10: B01)

			M										F									
			<1yr	1-4yrs	5-14yrs	15-24yrs	25-44yrs	45-64yrs	65-74yrs	75-84yrs	85+yrs	All Ages	<1yr	1-4yrs	5-14yrs	15-24yrs	25-44yrs	45-64yrs	65-74yrs	75-84yrs	85+yrs	All Ages
North	Quarter	1	0.0	73.5	22.6	1.1	1.2	0.9	0.0	0.0	0.0	6.1	0.0	81.4	28.6	1.2	1.0	0.5	1.3	0.0	0.0	6.7
		2	8.0	39.7	8.2	0.4	0.4	0.0	0.0	0.0	0.0	2.7	11.5	40.1	6.0	0.4	0.4	0.6	0.0	0.0	0.0	2.5
		3	60.0	64.7	11.3	0.5	0.7	0.2	0.0	0.0	0.0	4.6	18.1	61.0	9.5	1.3	0.6	0.3	0.0	0.0	0.0	3.9
		4	65.8	91.0	11.5	1.7	0.7	0.2	0.2	0.0	0.0	6.2	68.2	77.9	18.0	1.1	0.8	0.2	0.0	0.0	0.0	6.0
	Year	18/19	38.0	479.0	243.0	21.0	34.0	14.0	1.0	0.0	0.0	830.0	29.0	435.0	273.0	23.0	30.0	16.0	5.0	0.0	0.0	811.0
	Episodes	F/N	32.8	67.3	13.6	0.9	0.8	0.3	0.0	0.0	0.0	4.9	24.0	65.4	15.8	1.0	0.7	0.4	0.3	0.0	0.0	4.8
South	Quarter	1	0.0	73.9	27.0	1.2	1.1	0.2	0.0	0.0	0.0	6.9	0.0	63.5	20.7	1.9	1.4	0.5	0.0	0.0	0.0	5.6
		2	0.0	35.0	4.7	0.3	0.4	0.2	0.0	0.0	1.0	2.3	0.0	35.5	6.1	0.0	0.4	0.2	0.2	0.0	0.0	2.3
		3	27.2	46.7	7.7	0.8	0.5	0.4	0.0	0.3	0.0	3.4	28.6	47.0	12.6	1.2	0.5	0.3	0.2	0.0	0.0	3.8
		4	69.9	64.4	16.5	0.8	0.6	0.3	0.0	0.0	0.0	5.6	48.6	71.7	12.5	1.3	1.1	0.1	0.0	0.0	0.0	5.1
	Year	18/19	34.0	449.0	321.0	19.0	30.0	13.0	0.0	1.0	1.0	868.0	24.0	434.0	283.0	25.0	39.0	15.0	2.0	0.0	0.0	822.0
	Episodes	F/N	23.8	55.3	14.2	0.8	0.7	0.2	0.0	0.1	0.2	4.6	18.9	54.6	13.1	1.1	0.8	0.3	0.1	0.0	0.0	4.2
London	Quarter	1	0.0	61.9	42.8	3.6	0.8	0.7	0.0	0.0	0.0	9.8	0.0	54.5	39.0	2.7	2.0	0.4	0.0	0.0	0.0	8.9
		2	24.6	42.1	13.8	0.0	0.8	0.2	0.0	0.0	0.0	4.6	0.0	33.4	12.7	1.0	1.4	0.0	0.0	0.0	0.0	4.1
		3	13.1	55.9	24.1	3.1	1.2	0.8	0.0	0.0	0.0	7.2	11.0	46.7	23.3	0.9	1.3	0.4	0.0	0.0	0.0	6.1
		4	51.3	93.1	41.9	2.7	1.4	0.5	0.0	0.0	0.0	11.8	40.4	85.6	36.0	3.7	1.6	0.2	0.0	0.0	0.0	10.5
	Year	18/19	23.0	410.0	436.0	29.0	50.0	13.0	0.0	0.0	0.0	961.0	15.0	348.0	380.0	28.0	72.0	5.0	0.0	0.0	0.0	848.0
	Episodes	F/N	21.8	63.2	30.9	2.4	1.1	0.5	0.0	0.0	0.0	8.4	12.6	55.1	28.0	2.1	1.6	0.2	0.0	0.0	0.0	7.4
Midlands And East	Quarter	1	0.0	80.7	20.7	0.0	0.6	0.0	0.0	0.0	0.0	6.0	0.0	108.8	19.3	2.0	1.4	0.2	0.0	0.0	0.0	6.9
		2	32.8	34.9	6.4	0.0	0.4	0.0	0.0	0.0	0.0	2.5	0.0	42.9	7.1	1.6	0.9	0.6	0.0	0.0	0.0	3.1
		3	28.4	75.0	16.3	1.0	1.4	0.3	0.0	0.0	0.0	6.1	17.3	56.0	15.3	1.8	1.4	0.5	0.0	0.0	0.0	4.9
		4	61.1	89.0	18.2	0.8	0.8	0.3	0.0	0.7	0.0	7.2	68.9	80.5	18.1	1.7	1.0	0.0	0.4	0.0	1.2	6.6
	Year	18/19	16.0	246.0	147.0	4.0	16.0	4.0	0.0	1.0	0.0	434.0	14.0	228.0	136.0	14.0	22.0	7.0	1.0	0.0	1.0	423.0
	Episodes	F/N	30.0	70.1	15.5	0.4	0.8	0.2	0.0	0.2	0.0	5.5	21.2	72.7	15.0	1.7	1.2	0.3	0.1	0.0	0.3	5.4

Mean weekly incidence rate per 100,000 Persons.

Herpes Simplex (ICD10: B00)

		M										F									
		<1yr	1-4yrs	5-14yrs	15-24yrs	25-44yrs	45-64yrs	65-74yrs	75-84yrs	85+yrs	All Ages	<1yr	1-4yrs	5-14yrs	15-24yrs	25-44yrs	45-64yrs	65-74yrs	75-84yrs	85+yrs	All Ages
4 weekly	1	0	7	3	2	3	3	2	4	3	3	0	5	4	6	12	6	5	2	2	7
	2	0	4	2	2	3	2	1	1	0	2	0	4	3	6	11	6	3	1	2	6
	3	0	3	2	2	3	3	3	3	2	3	0	1	2	7	12	8	6	2	2	7
	4	0	3	2	3	2	2	3	2	2	2	0	4	2	9	12	8	3	2	4	8
	5	0	2	2	4	2	2	2	0	4	2	15	1	2	8	13	7	4	3	1	7
	6	0	3	4	2	3	2	0	2	2	2	0	4	4	9	11	5	3	1	2	6
	7	6	6	4	3	3	3	2	0	0	3	0	6	4	8	14	6	4	3	2	7
	8	0	5	3	4	2	3	2	2	1	3	0	3	3	10	12	8	4	2	2	7
	9	0	1	1	2	2	2	1	2	1	2	0	4	2	8	12	7	4	3	3	7
	10	3	4	4	1	3	2	2	2	3	3	0	4	4	10	13	8	3	2	3	8
	11	3	3	3	3	2	2	1	1	2	2	0	2	2	7	11	7	4	3	1	6
	12	0	3	3	2	2	2	2	0	0	2	0	3	3	6	11	7	5	2	2	7
	13	0	2	3	3	4	2	1	2	1	3	4	1	2	10	10	6	5	2	1	6
Quarter	1	0	5	2	2	3	3	2	2	2	3	0	3	3	7	12	6	5	2	3	7
	2	2	3	3	3	2	2	2	1	3	2	4	3	3	8	12	7	3	2	1	7
	3	0	4	3	2	3	2	2	2	1	2	0	4	3	9	12	7	3	2	3	7
	4	2	3	3	3	2	2	1	1	1	2	1	2	2	8	11	7	5	2	1	7
Year	18/19	3	87	193	166	414	307	83	36	16	1,305	3	76	175	551	1,789	929	205	66	36	3,830
Episodes	F/N	1	4	3	3	3	2	2	2	2	2	1	3	3	8	12	7	4	2	2	7

Mean weekly incidence rate per 100,000 Persons.

Herpes Simplex (ICD10: B00)

			M										F									
			<1yr	1-4yrs	5-14yrs	15-24yrs	25-44yrs	45-64yrs	65-74yrs	75-84yrs	85+yrs	All Ages	<1yr	1-4yrs	5-14yrs	15-24yrs	25-44yrs	45-64yrs	65-74yrs	75-84yrs	85+yrs	All Ages
North	Quarter	1	0	9	3	3	4	3	3	2	3	3	0	6	3	8	12	7	3	2	3	7
		2	0	7	5	3	3	2	2	2	0	3	18	7	5	10	15	6	2	1	1	8
		3	0	2	3	3	3	2	2	0	1	2	0	3	4	9	14	7	3	2	1	8
		4	3	3	5	1	2	2	3	1	1	2	5	2	3	9	12	7	5	2	1	7
	Year	18/19	1	33	73	57	127	99	38	11	4	443	3	26	64	210	554	294	63	20	8	1,242
	Episodes	F/N	1	5	4	3	3	2	2	1	1	3	6	4	4	9	13	7	3	2	2	7
South	Quarter	1	0	3	1	1	3	3	2	2	2	2	0	1	3	9	12	6	4	3	5	7
		2	0	3	3	3	2	2	1	1	1	2	0	2	3	8	13	7	3	2	0	7
		3	0	2	3	2	2	2	2	1	1	2	0	5	1	9	13	7	3	2	4	7
		4	0	2	2	3	3	1	1	0	2	2	0	2	3	9	11	6	5	1	2	7
	Year	18/19	0	19	53	53	124	93	28	11	7	388	0	21	55	203	577	336	80	26	19	1,317
	Episodes	F/N	0	2	2	2	3	2	1	1	2	2	0	3	3	9	12	7	4	2	3	7
London	Quarter	1	0	3	4	2	3	2	3	4	0	3	0	5	3	4	10	6	7	0	2	7
		2	7	3	3	3	2	3	3	2	4	3	0	3	3	5	9	7	3	2	0	6
		3	0	6	2	2	3	3	2	1	4	3	0	4	2	5	8	7	5	3	5	6
		4	3	3	3	3	2	3	1	1	0	2	0	3	1	7	8	6	5	5	2	6
	Year	18/19	2	24	41	33	119	73	11	6	2	311	0	22	29	70	415	146	30	10	4	726
	Episodes	F/N	2	4	3	3	3	3	2	2	2	3	0	4	2	5	9	7	5	3	2	6
Midlands And East	Quarter	1	0	4	2	2	0	3	0	1	2	2	0	2	2	5	13	5	4	2	0	6
		2	0	0	0	5	2	2	1	1	5	2	0	1	3	10	13	8	5	4	4	8
		3	0	6	4	1	3	2	1	3	0	3	0	5	3	11	14	8	2	1	3	8
		4	0	3	3	3	3	2	1	1	0	2	0	1	3	7	11	7	4	1	0	6
	Year	18/19	0	11	26	23	44	42	6	8	3	163	0	7	27	68	243	153	32	10	5	545
	Episodes	F/N	0	3	3	3	2	2	1	2	2	2	0	2	3	8	13	7	4	2	2	7

Mean weekly incidence rate per 100,000 Persons.

Herpes Zoster (ICD10: B02)

		M										F									
		<1yr	1-4yrs	5-14yrs	15-24yrs	25-44yrs	45-64yrs	65-74yrs	75-84yrs	85+yrs	All Ages	<1yr	1-4yrs	5-14yrs	15-24yrs	25-44yrs	45-64yrs	65-74yrs	75-84yrs	85+yrs	All Ages
4 weekly	1	0	1	4	3	4	7	19	16	16	7	0	0	6	6	6	11	18	19	33	10
	2	0	0	2	1	3	7	13	16	13	5	0	1	5	3	6	12	11	21	38	9
	3	0	2	4	1	4	6	14	18	13	6	0	1	6	4	5	13	15	16	30	9
	4	0	1	2	4	4	6	11	10	28	6	0	1	4	3	5	13	16	17	43	10
	5	0	2	4	2	4	6	10	13	20	5	0	2	5	6	5	13	15	20	23	9
	6	0	2	6	3	2	6	9	13	14	5	0	1	6	4	6	12	19	18	22	10
	7	0	1	4	3	4	6	10	14	21	6	0	0	5	5	5	11	20	20	24	9
	8	0	0	4	4	4	7	13	12	25	6	0	2	3	4	6	10	18	24	20	9
	9	0	1	2	2	2	7	6	9	16	4	0	2	3	1	4	11	14	13	17	7
	10	0	1	3	3	3	7	14	11	24	6	0	2	3	3	5	13	20	15	17	9
	11	3	1	4	2	3	7	13	14	19	6	0	1	4	3	6	11	17	17	41	9
	12	0	2	3	2	3	7	12	8	12	5	0	0	4	4	6	12	16	17	17	9
	13	0	1	4	2	2	7	13	11	21	5	0	1	4	5	4	11	14	20	27	8
Quarter	1	0	1	3	2	4	7	15	16	18	6	0	0	6	4	6	12	15	18	35	9
	2	0	1	4	3	3	6	9	12	18	5	0	1	5	4	6	13	17	19	27	9
	3	0	1	3	3	3	7	11	12	20	5	0	2	4	3	5	11	18	18	19	8
	4	1	1	4	2	3	7	14	11	18	5	0	1	4	4	5	12	16	18	27	9
Year	18/19	1	26	242	188	490	927	619	377	191	3,061	0	31	299	247	810	1,646	867	655	485	5,040
Episodes	F/N	0	1	4	3	3	7	12	13	19	6	0	1	5	4	5	12	16	18	27	9

Mean weekly incidence rate per 100,000 Persons.

Herpes Zoster (ICD10: B02)

			M										F									
			<1yr	1-4yrs	5-14yrs	15-24yrs	25-44yrs	45-64yrs	65-74yrs	75-84yrs	85+yrs	All Ages	<1yr	1-4yrs	5-14yrs	15-24yrs	25-44yrs	45-64yrs	65-74yrs	75-84yrs	85+yrs	All Ages
North	Quarter	1	0	3	3	3	4	7	19	21	15	7	0	1	6	4	6	13	19	24	42	11
		2	0	1	5	4	4	7	13	19	15	7	0	0	7	4	6	13	19	24	30	11
		3	0	2	5	3	3	7	12	13	21	6	0	3	5	5	5	12	17	19	22	9
		4	0	1	4	2	3	8	10	11	24	6	0	1	6	2	5	14	19	20	27	10
	Year	18/19	0	13	79	69	141	308	227	147	61	1,045	0	10	106	84	237	560	327	243	162	1,729
	Episodes	F/N	0	2	4	3	3	7	14	16	19	6	0	1	6	4	6	13	18	22	31	10
South	Quarter	1	0	1	4	3	3	7	10	16	21	6	0	1	9	6	6	13	16	20	30	11
		2	0	1	6	3	4	6	10	11	16	6	0	3	7	3	7	12	14	19	28	10
		3	0	0	2	4	3	6	13	12	22	6	0	3	4	2	5	10	16	15	25	8
		4	3	0	4	3	3	5	13	9	11	5	0	1	5	4	6	13	11	20	28	10
	Year	18/19	1	4	98	81	161	304	231	141	76	1,097	0	16	133	87	286	604	296	261	206	1,889
	Episodes	F/N	1	0	4	3	3	6	12	12	18	6	0	2	6	4	6	12	14	19	28	10
London	Quarter	1	0	0	3	1	4	5	15	16	15	4	0	0	2	2	4	9	10	19	35	6
		2	0	1	2	3	2	5	6	5	21	3	0	1	2	5	4	8	16	19	21	6
		3	0	1	0	1	3	5	11	12	15	3	0	1	2	2	4	10	20	18	16	6
		4	0	1	2	1	2	5	14	8	11	3	0	0	1	3	3	8	19	16	27	5
	Year	18/19	0	4	28	18	118	123	59	29	16	395	0	3	25	41	172	194	94	65	43	637
	Episodes	F/N	0	1	2	2	3	5	11	10	16	4	0	0	2	3	4	9	16	18	25	6
Midlands And East	Quarter	1	0	0	2	1	3	9	17	10	21	7	0	0	6	5	7	12	16	11	32	10
		2	0	3	4	2	4	8	8	13	20	6	0	1	3	6	5	18	19	12	29	11
		3	0	0	5	3	4	8	7	10	20	6	0	0	4	2	5	12	18	21	15	9
		4	0	3	4	3	3	10	16	15	28	8	0	1	3	4	7	12	15	16	27	10
	Year	18/19	0	5	37	20	70	192	102	60	38	524	0	2	35	35	115	288	150	86	74	785
	Episodes	F/N	0	1	4	2	4	9	12	12	22	7	0	1	4	4	6	13	17	15	26	10

Mean weekly incidence rate per 100,000 Persons.

Infections of Skin & Subcutaneous Tissue (ICD10: L00-L08)

		M										F									
		<1yr	1-4yrs	5-14yrs	15-24yrs	25-44yrs	45-64yrs	65-74yrs	75-84yrs	85+yrs	All Ages	<1yr	1-4yrs	5-14yrs	15-24yrs	25-44yrs	45-64yrs	65-74yrs	75-84yrs	85+yrs	All Ages
4 weekly	1	0	90	70	48	44	54	95	114	167	63	0	80	62	51	66	72	87	133	206	76
	2	116	64	61	53	44	55	78	107	158	59	0	58	60	52	70	84	77	119	176	76
	3	423	68	61	40	50	68	84	113	147	64	151	67	58	56	75	102	112	133	192	88
	4	235	64	48	39	50	58	81	99	167	58	152	70	45	53	63	78	91	124	174	74
	5	150	69	52	36	43	48	59	98	121	52	151	54	60	47	56	54	73	111	185	64
	6	108	83	48	40	38	42	65	94	112	49	190	80	44	49	51	54	71	86	188	60
	7	119	89	51	32	35	44	54	83	142	47	128	73	44	45	46	46	63	93	134	54
	8	86	76	46	35	31	42	52	88	134	46	138	70	42	41	47	44	61	81	152	52
	9	102	69	39	26	27	38	56	70	106	39	62	49	41	35	35	39	56	84	136	45
	10	78	80	47	36	32	37	53	76	112	43	80	65	47	45	46	47	53	88	152	54
	11	113	67	39	31	32	39	52	87	132	43	87	63	41	42	45	45	67	86	174	53
	12	81	77	46	34	33	40	53	90	164	45	57	74	51	43	45	48	60	93	158	54
	13	71	62	40	31	31	38	60	93	112	43	53	55	40	40	44	46	59	87	154	51
Quarter	1	168	76	63	47	46	58	85	109	159	62	57	70	59	52	69	84	92	128	191	79
	2	159	71	49	37	42	48	67	96	131	51	161	68	49	48	56	59	73	103	173	64
	3	92	79	46	32	30	41	53	80	123	44	96	62	43	42	43	43	60	85	147	51
	4	85	70	42	33	32	39	55	89	133	44	66	65	44	42	45	46	61	90	161	53
Year	18/19	238	1,837	3,271	2,423	5,700	6,503	3,221	2,662	1,422	27,277	188	1,554	3,061	3,016	7,860	7,791	3,747	3,480	2,942	33,639
Episodes	F/N	127	74	50	37	38	46	65	94	137	50	94	66	49	46	53	59	72	102	168	62

Mean weekly incidence rate per 100,000 Persons.

Infections of Skin & Subcutaneous Tissue (ICD10: L00-L08)

			M										F									
			<1yr	1-4yrs	5-14yrs	15-24yrs	25-44yrs	45-64yrs	65-74yrs	75-84yrs	85+yrs	All Ages	<1yr	1-4yrs	5-14yrs	15-24yrs	25-44yrs	45-64yrs	65-74yrs	75-84yrs	85+yrs	All Ages
North	Quarter	1	128	83	64	49	52	62	79	113	184	66	119	74	66	48	77	83	101	127	215	84
		2	188	75	50	38	45	54	72	116	140	57	139	78	54	49	62	61	71	115	178	68
		3	131	86	53	34	35	46	56	81	136	49	108	71	50	46	47	44	59	82	164	55
		4	91	92	48	37	37	43	58	92	129	49	85	71	52	44	51	50	66	95	163	59
	Year	18/19	76	589	990	851	1,856	2,193	1,110	945	456	9,066	63	480	976	1,059	2,460	2,473	1,298	1,169	965	10,943
	Episodes	F/N	134	84	54	40	43	51	66	101	148	56	113	74	56	47	60	60	75	105	181	67
South	Quarter	1	188	85	69	48	49	61	81	116	167	66	82	72	62	46	70	84	98	134	191	82
		2	103	69	59	35	44	50	65	83	136	54	215	67	51	48	55	60	68	102	175	65
		3	95	90	48	30	28	37	54	79	117	44	76	63	47	40	42	42	55	84	143	51
		4	88	64	41	31	31	36	54	78	137	43	52	67	44	44	43	43	53	79	152	52
	Year	18/19	66	622	1,236	840	1,791	2,307	1,232	1,028	611	9,733	54	528	1,114	1,024	2,453	2,830	1,425	1,365	1,231	12,024
	Episodes	F/N	120	77	54	36	38	46	64	90	140	52	106	67	51	45	53	58	69	101	166	63
London	Quarter	1	356	62	50	35	33	46	76	95	128	45	27	60	47	53	50	79	83	119	200	63
		2	253	54	41	38	31	41	72	101	124	42	74	46	45	43	43	58	75	82	181	52
		3	80	55	35	29	24	37	45	86	98	34	66	50	34	37	32	42	59	78	141	40
		4	110	46	36	31	21	31	40	101	146	32	64	35	30	29	34	40	70	81	166	40
	Year	18/19	76	347	569	403	1,244	948	295	267	128	4,277	39	297	522	517	1,825	1,204	410	324	301	5,439
	Episodes	F/N	203	55	41	34	27	39	59	96	124	38	57	48	39	41	40	55	72	90	172	49
Midlands And East	Quarter	1	0	73	70	54	51	64	105	113	155	71	0	72	63	62	79	91	88	132	160	87
		2	93	86	44	35	47	45	59	82	124	52	215	82	46	51	63	59	76	114	158	69
		3	61	86	47	37	34	43	55	73	143	48	134	65	43	47	50	44	67	97	139	57
		4	51	77	44	32	41	43	68	86	122	50	62	87	50	50	50	51	53	104	162	60
	Year	18/19	20	279	476	329	809	1,055	584	422	227	4,201	32	249	449	416	1,122	1,284	614	622	445	5,233
	Episodes	F/N	50	81	52	40	43	49	72	89	136	55	101	77	51	52	61	62	71	112	155	68

Mean weekly incidence rate per 100,000 Persons.

Scabies (ICD10: B86)

		M										F									
		<1yr	1-4yrs	5-14yrs	15-24yrs	25-44yrs	45-64yrs	65-74yrs	75-84yrs	85+yrs	All Ages	<1yr	1-4yrs	5-14yrs	15-24yrs	25-44yrs	45-64yrs	65-74yrs	75-84yrs	85+yrs	All Ages
4 weekly	1	0.0	1.9	2.4	2.2	1.1	1.0	0.2	1.3	0.0	1.3	0.0	3.3	1.7	3.8	0.8	0.9	0.0	0.8	3.1	1.4
	2	0.0	0.0	0.7	2.8	1.4	0.5	0.8	0.7	2.6	1.1	0.0	1.2	0.4	1.4	0.8	0.9	0.9	1.3	2.6	1.0
	3	0.0	0.6	1.2	1.7	1.3	0.4	1.4	0.4	3.1	1.1	0.0	1.3	2.6	2.1	0.8	0.7	0.5	0.6	1.2	1.1
	4	0.0	0.6	1.5	0.8	0.8	0.9	1.5	2.0	1.2	1.0	0.0	2.3	1.2	1.7	1.3	1.8	0.6	3.4	6.9	1.8
	5	0.0	3.1	4.3	3.7	1.4	0.9	0.8	2.1	0.7	1.9	0.0	2.4	3.0	3.1	2.0	1.9	1.0	0.3	0.4	1.9
	6	0.0	3.5	2.2	3.0	1.4	1.3	0.8	0.4	0.8	1.7	8.1	1.1	2.5	3.1	1.6	1.6	1.0	0.3	0.5	1.7
	7	6.3	2.4	2.8	3.1	1.1	0.7	0.6	0.4	0.0	1.4	5.7	2.6	2.3	3.0	1.9	1.6	2.2	0.3	2.4	2.0
	8	0.0	3.2	2.9	4.4	0.5	1.5	1.0	1.3	5.4	1.8	0.0	1.4	3.1	4.6	1.4	1.1	0.0	1.2	0.4	1.7
	9	3.7	1.3	1.7	2.5	1.3	1.2	0.7	0.6	0.7	1.4	0.0	1.3	2.5	2.5	2.0	1.0	0.3	0.8	0.6	1.6
	10	6.1	2.0	3.3	2.7	1.7	1.4	0.9	0.0	0.7	1.8	5.9	3.8	4.1	3.2	1.7	2.1	1.3	0.7	0.5	2.2
	11	2.4	3.2	1.7	3.2	1.4	1.1	0.0	1.1	0.0	1.5	0.0	0.8	1.9	4.7	1.6	0.8	0.7	0.5	1.0	1.6
	12	2.5	2.1	1.5	3.7	1.4	1.2	0.8	0.0	0.0	1.5	2.5	3.3	2.9	1.3	1.6	1.1	1.6	1.7	0.4	1.6
	13	2.1	2.9	2.2	2.4	0.8	1.1	0.6	1.4	1.9	1.3	0.0	4.0	1.9	2.9	1.3	0.7	0.6	1.4	0.0	1.4
Quarter	1	0.0	1.0	1.4	2.2	1.2	0.6	0.7	0.8	1.6	1.1	0.0	1.9	1.6	2.4	0.8	0.9	0.4	1.0	2.2	1.2
	2	2.0	2.5	3.1	2.9	1.2	1.1	1.2	1.5	0.8	1.6	2.5	2.4	2.3	2.8	1.8	1.8	1.1	1.1	2.8	1.9
	3	2.2	2.3	2.5	3.2	1.2	1.2	0.7	0.6	2.1	1.6	2.7	2.2	3.1	3.4	1.7	1.4	0.9	0.7	0.6	1.9
	4	3.0	2.5	1.8	3.1	1.2	1.2	0.5	0.8	0.6	1.5	1.6	2.5	2.3	3.0	1.5	0.9	0.9	1.2	0.6	1.6
Year	18/19	7.0	50.0	136.0	207.0	183.0	139.0	34.0	22.0	15.0	793.0	5.0	51.0	150.0	218.0	233.0	167.0	46.0	33.0	30.0	933.0
Episodes	F/N	1.8	2.1	2.2	2.8	1.2	1.0	0.8	0.9	1.3	1.4	1.7	2.2	2.3	2.9	1.4	1.2	0.8	1.0	1.6	1.6

Mean weekly incidence rate per 100,000 Persons.

Scabies (ICD10: B86)

			M										F									
			<1yr	1-4yrs	5-14yrs	15-24yrs	25-44yrs	45-64yrs	65-74yrs	75-84yrs	85+yrs	All Ages	<1yr	1-4yrs	5-14yrs	15-24yrs	25-44yrs	45-64yrs	65-74yrs	75-84yrs	85+yrs	All Ages
North	Quarter	1	0.0	2.0	2.0	3.5	1.6	1.2	0.8	1.8	0.0	1.7	0.0	1.4	3.0	4.8	1.3	0.9	0.8	0.4	5.5	1.9
		2	0.0	5.1	3.9	4.7	1.8	1.1	1.3	2.8	1.4	2.4	9.9	3.5	4.6	6.2	3.0	2.6	1.0	3.0	10.1	3.6
		3	4.6	4.2	4.2	7.5	2.0	1.6	1.1	1.2	2.5	2.8	10.7	4.8	6.8	6.7	3.4	2.4	1.3	1.6	0.7	3.6
		4	8.9	4.8	3.0	5.5	1.7	1.5	0.4	0.4	2.3	2.3	3.5	3.0	4.5	5.9	2.6	1.2	1.2	1.2	1.9	2.6
	Year	18/19	4.0	29.0	62.0	119.0	80.0	58.0	15.0	14.0	5.0	386.0	4.0	22.0	86.0	135.0	111.0	74.0	19.0	17.0	22.0	490.0
	Episodes	F/N	3.3	4.0	3.3	5.3	1.8	1.3	0.9	1.6	1.5	2.3	5.9	3.1	4.7	5.9	2.5	1.7	1.1	1.5	4.6	2.9
South	Quarter	1	0.0	0.0	0.4	1.3	0.5	0.5	0.0	0.4	1.1	0.5	0.0	0.6	0.8	1.0	0.6	0.4	0.2	0.6	1.1	0.6
		2	0.0	0.0	1.1	1.8	0.4	0.4	0.6	0.0	1.9	0.7	0.0	2.1	1.1	0.9	1.2	1.3	0.6	0.3	1.1	1.1
		3	0.0	0.5	0.9	1.8	0.9	0.7	0.0	0.3	3.5	0.9	0.0	0.5	0.5	2.9	0.4	0.9	0.9	0.3	0.5	0.9
		4	0.0	0.4	0.5	1.9	0.4	0.5	0.9	0.0	0.0	0.6	0.0	0.0	1.3	2.1	0.9	0.6	1.3	1.0	0.5	1.0
	Year	18/19	0.0	2.0	16.0	41.0	26.0	28.0	8.0	2.0	7.0	130.0	0.0	6.0	21.0	41.0	36.0	41.0	17.0	8.0	6.0	176.0
	Episodes	F/N	0.0	0.2	0.7	1.7	0.5	0.5	0.4	0.2	1.6	0.7	0.0	0.8	0.9	1.7	0.7	0.8	0.8	0.6	0.8	0.9
London	Quarter	1	0.0	1.9	2.1	3.2	0.8	0.3	0.8	0.0	0.0	1.2	0.0	2.1	2.7	1.3	1.2	1.1	0.0	2.2	2.1	1.4
		2	7.8	1.3	4.0	2.5	1.4	2.1	1.7	3.0	0.0	2.1	0.0	2.8	1.6	2.4	1.6	1.5	0.7	1.2	0.0	1.7
		3	4.1	1.2	2.5	2.8	0.7	1.7	0.8	0.0	0.0	1.4	0.0	1.3	2.9	1.4	1.2	0.9	1.4	1.1	0.0	1.4
		4	3.1	1.3	2.1	3.3	1.3	1.7	0.7	2.7	0.0	1.7	3.1	3.2	1.1	2.7	1.6	1.0	0.7	1.2	0.0	1.6
	Year	18/19	3.0	9.0	37.0	36.0	50.0	36.0	5.0	4.0	0.0	180.0	1.0	14.0	28.0	26.0	66.0	25.0	4.0	5.0	1.0	170.0
	Episodes	F/N	3.7	1.4	2.7	2.9	1.1	1.4	1.0	1.4	0.0	1.6	0.8	2.4	2.1	1.9	1.4	1.1	0.7	1.4	0.6	1.5
Midlands And East	Quarter	1	0.0	0.0	1.1	0.6	1.9	0.4	1.1	0.9	5.5	1.1	0.0	3.4	0.0	2.4	0.0	1.1	0.6	0.8	0.0	0.8
		2	0.0	3.6	3.2	2.5	1.2	0.8	1.1	0.0	0.0	1.5	0.0	1.3	1.8	1.8	1.4	1.7	2.0	0.0	0.0	1.5
		3	0.0	3.3	2.6	0.5	1.2	0.7	1.0	0.8	2.3	1.2	0.0	2.2	2.1	2.7	1.8	1.6	0.0	0.0	1.4	1.5
		4	0.0	3.7	1.8	1.5	1.5	1.1	0.0	0.0	0.0	1.2	0.0	3.8	2.2	1.2	0.9	0.8	0.4	1.2	0.0	1.1
	Year	18/19	0.0	10.0	21.0	11.0	27.0	17.0	6.0	2.0	3.0	97.0	0.0	9.0	15.0	16.0	20.0	27.0	6.0	3.0	1.0	97.0
	Episodes	F/N	0.0	2.6	2.1	1.3	1.5	0.7	0.8	0.4	2.0	1.2	0.0	2.7	1.5	2.0	1.0	1.3	0.7	0.5	0.3	1.2

Mean weekly incidence rate per 100,000 Persons.

Symptoms and signs involving the skin and subcutaneous tissue (ICD10: R20-R23)

		M										F									
		<1yr	1-4yrs	5-14yrs	15-24yrs	25-44yrs	45-64yrs	65-74yrs	75-84yrs	85+yrs	All Ages	<1yr	1-4yrs	5-14yrs	15-24yrs	25-44yrs	45-64yrs	65-74yrs	75-84yrs	85+yrs	All Ages
4 weekly	1	0	142	60	22	25	31	54	72	94	42	0	125	67	48	48	50	71	69	111	60
	2	810	117	49	21	21	29	38	61	78	35	2,131	126	53	35	38	47	54	73	73	50
	3	420	131	37	22	19	28	44	58	84	35	389	120	43	39	42	50	53	83	93	52
	4	223	91	30	18	24	27	40	69	67	33	113	83	35	31	38	42	62	74	80	46
	5	219	93	35	17	21	23	38	58	70	31	152	94	37	33	40	43	50	61	63	45
	6	268	115	39	20	21	25	38	45	72	33	154	122	37	34	38	45	54	64	74	47
	7	168	125	27	16	21	28	36	43	71	31	184	127	33	36	39	42	44	50	59	45
	8	187	82	31	19	18	24	33	50	65	29	182	111	35	31	33	38	41	51	54	40
	9	175	67	24	13	18	21	31	41	60	25	138	64	28	23	27	29	31	42	53	31
	10	201	85	29	22	19	28	40	63	73	32	179	90	37	36	38	38	44	48	63	43
	11	168	74	30	23	20	25	43	50	76	31	225	78	38	34	39	41	46	62	81	45
	12	147	90	34	20	22	27	42	55	67	33	236	73	36	37	42	42	47	63	113	47
	13	191	86	35	15	18	26	45	60	77	32	143	74	36	30	38	37	43	56	78	42
Quarter	1	358	127	49	21	21	29	46	64	88	37	720	122	54	41	42	48	60	74	92	54
	2	245	105	34	19	22	25	37	54	68	32	157	107	37	32	39	44	54	63	71	46
	3	175	84	27	17	19	25	36	49	63	29	167	92	32	31	34	36	38	46	55	39
	4	172	84	33	19	20	26	43	55	75	32	201	75	37	34	39	40	46	61	89	44
Year	18/19	440	2,516	2,274	1,248	3,300	3,777	2,065	1,596	744	17,960	417	2,368	2,464	2,296	6,047	5,623	2,560	2,131	1,409	25,315
Episodes	F/N	240	100	36	19	21	26	41	56	74	33	319	99	40	35	39	42	50	61	77	46

Mean weekly incidence rate per 100,000 Persons.

Symptoms and signs involving the skin and subcutaneous tissue (ICD10: R20-R23)

			M										F									
			<1yr	1-4yrs	5-14yrs	15-24yrs	25-44yrs	45-64yrs	65-74yrs	75-84yrs	85+yrs	All Ages	<1yr	1-4yrs	5-14yrs	15-24yrs	25-44yrs	45-64yrs	65-74yrs	75-84yrs	85+yrs	All Ages
North	Quarter	1	75	158	56	19	24	32	43	58	68	39	264	159	60	37	44	48	59	87	101	57
		2	329	132	38	21	25	30	38	70	64	37	139	121	46	34	45	47	59	70	89	52
		3	189	91	31	18	21	26	41	60	57	32	176	101	38	35	40	39	42	51	71	44
		4	203	99	34	23	22	30	51	66	62	36	245	83	45	35	45	40	54	59	89	49
	Year	18/19	135	809	720	443	1,026	1,283	745	605	196	5,962	135	734	824	807	1,834	1,814	949	742	469	8,308
	Episodes	F/N	197	121	40	20	23	30	43	64	63	36	207	117	47	35	43	43	54	67	88	50
South	Quarter	1	952	132	40	19	20	30	45	57	82	36	116	103	44	34	42	45	50	78	106	50
		2	153	98	26	13	19	22	38	44	70	28	228	96	32	30	36	38	42	63	82	43
		3	181	87	26	14	17	25	37	45	78	29	167	89	30	27	33	35	39	48	58	38
		4	151	76	26	17	19	25	44	54	69	31	172	78	31	33	35	35	42	60	83	42
	Year	18/19	120	784	678	374	906	1,310	816	584	330	5,902	120	719	743	713	1,733	1,924	915	859	614	8,340
	Episodes	F/N	370	99	30	16	19	26	41	50	75	31	170	92	34	31	37	38	43	63	83	43
London	Quarter	1	407	137	54	31	27	33	59	79	99	42	1,851	138	66	56	50	63	81	67	87	63
		2	282	113	44	24	23	28	37	62	49	35	206	125	44	37	41	50	67	68	43	50
		3	175	80	29	20	17	26	39	48	53	28	184	93	35	37	30	40	38	41	47	39
		4	197	84	38	20	20	26	37	49	77	31	187	67	35	34	37	45	48	61	74	43
	Year	18/19	133	656	573	288	1,005	690	220	166	72	3,803	110	652	601	528	1,804	1,094	331	214	110	5,444
	Episodes	F/N	268	105	41	24	22	28	43	60	70	34	630	106	45	41	40	50	59	60	63	49
Midlands And East	Quarter	1	0	82	45	15	14	22	38	63	103	31	649	86	44	37	34	36	51	65	75	44
		2	216	77	28	18	20	22	33	41	88	29	54	86	27	27	33	41	47	51	69	41
		3	156	76	23	18	20	22	24	44	66	27	143	84	26	25	32	30	33	46	43	34
		4	136	76	33	16	20	23	40	52	92	31	199	73	36	33	40	40	37	63	110	45
	Year	18/19	52	267	303	143	363	494	284	241	146	2,293	52	263	296	248	676	791	365	316	216	3,223
	Episodes	F/N	124	78	33	17	18	22	34	50	87	29	269	82	33	31	35	37	42	56	74	41

Mean weekly incidence rate per 100,000 Persons.

Impetigo (ICD10 : L01)

		M										F									
		<1yr	1-4yrs	5-14yrs	15-24yrs	25-44yrs	45-64yrs	65-74yrs	75-84yrs	85+yrs	All Ages	<1yr	1-4yrs	5-14yrs	15-24yrs	25-44yrs	45-64yrs	65-74yrs	75-84yrs	85+yrs	All Ages
4 weekly	1	0	30	23	7	2	2	1	0	1	6	0	30	22	8	6	4	2	1	2	8
	2	0	15	15	4	1	2	0	1	2	4	0	21	13	4	3	2	0	0	2	4
	3	0	20	18	2	4	0	1	3	0	5	72	23	15	6	4	2	3	1	0	5
	4	18	19	16	4	3	2	2	2	0	5	0	24	12	6	4	2	2	2	0	5
	5	19	29	19	5	2	1	1	1	0	5	0	27	24	6	4	2	1	3	1	7
	6	15	48	16	4	1	2	1	2	1	6	0	43	14	6	5	2	1	1	2	6
	7	0	53	19	4	2	1	0	1	3	6	11	47	12	4	4	2	1	2	0	6
	8	0	51	17	3	2	2	1	1	1	6	5	44	16	5	4	2	2	3	2	6
	9	17	28	15	2	2	1	1	1	0	4	0	25	15	6	4	2	1	2	2	5
	10	15	42	18	4	2	1	2	3	1	6	16	34	19	6	4	2	2	3	5	7
	11	15	28	13	5	2	1	1	1	5	5	5	25	14	5	4	2	3	3	2	5
	12	12	35	14	4	3	1	1	1	2	5	2	33	18	6	4	2	2	2	1	6
	13	8	22	10	3	2	2	1	0	2	4	8	23	14	6	4	2	1	1	2	5
Quarter	1	0	23	18	5	2	1	1	1	1	5	21	26	17	5	5	3	2	1	1	6
	2	16	34	17	4	2	1	1	1	1	5	0	34	16	6	4	2	1	2	1	6
	3	10	43	17	3	2	1	1	1	1	6	9	36	16	5	4	2	2	2	2	6
	4	11	30	13	4	2	2	1	1	3	5	6	27	16	6	4	2	2	2	2	6
Year	18/19	26	820	1,106	261	325	211	54	39	17	2,859	13	727	1,034	390	625	323	91	65	34	3,302
Episodes	F/N	9	32	16	4	2	1	1	1	1	5	9	31	16	6	4	2	2	2	2	6

Mean weekly incidence rate per 100,000 Persons.

Impetigo (ICD10: L01)

			M										F									
			<1yr	1-4yrs	5-14yrs	15-24yrs	25-44yrs	45-64yrs	65-74yrs	75-84yrs	85+yrs	All Ages	<1yr	1-4yrs	5-14yrs	15-24yrs	25-44yrs	45-64yrs	65-74yrs	75-84yrs	85+yrs	All Ages
North	Quarter	1	0	29	18	6	3	2	1	1	3	5	0	30	19	5	6	3	2	0	2	6
		2	22	34	19	5	2	1	1	1	1	5	0	38	17	9	5	2	2	4	2	7
		3	13	45	20	3	2	2	1	1	1	6	4	46	19	6	4	3	2	2	1	7
		4	9	43	16	5	2	1	1	2	2	6	6	30	18	8	5	2	2	2	1	6
	Year	18/19	7	268	339	100	98	72	14	14	6	918	3	237	323	154	206	102	38	21	7	1,091
	Episodes	F/N	11	38	18	5	2	2	1	1	2	5	2	36	18	7	5	2	2	2	1	7
South	Quarter	1	0	25	21	3	2	2	0	2	1	5	82	29	21	7	4	3	1	3	3	7
		2	9	37	28	4	3	2	2	1	1	7	0	37	20	7	4	2	2	2	2	7
		3	7	50	19	4	2	2	1	2	2	6	10	33	20	6	5	3	1	1	3	7
		4	11	29	14	4	2	1	1	1	3	5	8	33	17	6	4	3	1	1	3	6
	Year	18/19	7	288	473	91	118	80	23	17	8	1,105	6	261	421	146	214	142	31	24	19	1,264
	Episodes	F/N	7	35	21	4	2	2	1	1	2	6	26	33	19	6	4	3	1	2	3	7
London	Quarter	1	0	15	13	3	1	1	0	1	0	3	0	18	10	3	2	2	1	0	0	4
		2	9	23	9	4	2	1	2	0	0	4	0	15	13	3	3	2	1	2	0	4
		3	4	35	10	3	1	1	1	1	0	4	0	25	10	3	2	0	1	1	2	4
		4	19	14	8	2	1	1	0	0	4	3	4	14	7	2	3	1	2	0	2	3
	Year	18/19	8	139	138	33	59	22	3	2	1	405	1	112	136	36	105	26	7	3	2	428
	Episodes	F/N	8	21	10	3	1	1	1	1	1	4	1	18	10	3	2	1	1	1	1	4
Midlands And East	Quarter	1	0	23	22	8	4	1	2	0	0	6	0	26	17	7	6	3	3	1	2	6
		2	23	43	13	3	2	2	1	3	2	5	0	46	16	6	4	3	1	0	1	6
		3	15	42	19	2	1	1	1	1	0	5	22	41	14	7	5	2	2	5	3	6
		4	4	35	13	5	4	2	3	1	2	6	5	32	21	7	6	2	1	5	3	7
	Year	18/19	4	125	156	37	50	37	14	6	2	431	3	117	154	54	100	53	15	17	6	519
	Episodes	F/N	10	35	17	5	3	2	2	1	1	6	6	36	17	7	5	3	2	3	2	7

Mean weekly incidence rate per 100,000 Persons.

Disorders of The Peripheral Nervous System (ICD10: G50-G64,G70-G72)

		M										F									
		<1yr	1-4yrs	5-14yrs	15-24yrs	25-44yrs	45-64yrs	65-74yrs	75-84yrs	85+yrs	All Ages	<1yr	1-4yrs	5-14yrs	15-24yrs	25-44yrs	45-64yrs	65-74yrs	75-84yrs	85+yrs	All Ages
4 weekly	1	0	0	1	3	5	15	20	31	27	10	0	0	0	1	14	23	21	28	28	14
	2	0	0	0	2	3	11	17	25	22	7	0	1	0	3	10	20	16	27	18	12
	3	0	0	0	1	4	9	15	20	16	6	0	0	1	2	9	20	13	23	22	11
	4	0	0	0	1	3	11	14	18	21	6	0	0	2	4	8	16	15	21	11	10
	5	0	1	0	1	5	10	16	12	12	6	0	0	1	3	10	17	15	19	18	11
	6	0	0	0	1	5	9	14	24	17	7	0	1	1	2	12	21	15	22	15	12
	7	0	0	0	1	6	9	13	23	24	7	0	0	1	2	9	16	13	24	20	10
	8	0	0	0	1	5	10	19	23	17	7	0	0	0	1	11	18	17	22	20	12
	9	0	0	1	1	4	10	13	16	14	6	0	0	0	1	8	15	12	16	12	8
	10	0	0	0	2	6	10	12	19	24	7	0	0	1	1	10	22	18	24	25	13
	11	0	0	0	1	4	11	17	19	11	7	0	0	0	2	11	18	13	19	17	11
	12	0	0	0	2	6	12	14	15	25	7	0	0	0	3	11	21	21	24	20	12
	13	0	0	0	1	5	10	11	16	22	6	0	0	0	3	10	18	16	20	23	11
Quarter	1	0	0	0	2	4	12	18	25	22	8	0	0	0	2	11	21	17	26	22	12
	2	0	0	0	1	5	10	14	18	17	7	0	0	1	3	10	18	15	21	16	11
	3	0	0	1	1	5	9	14	21	19	7	0	0	0	1	10	18	15	21	19	11
	4	0	0	0	1	5	11	14	17	20	7	0	0	0	3	11	20	17	21	21	12
Year	18/19	0	1	22	87	726	1,497	748	579	203	3,863	0	4	22	158	1,597	2,588	869	761	375	6,374
Episodes	F/N	0	0	0	1	5	11	15	20	20	7	0	0	0	2	10	19	16	22	19	11

6. Disorders Affecting the Nervous System:

Mean weekly incidence rate per 100,000 Persons.

Disorders of The Peripheral Nervous System (ICD10: G50-G64,G70-G72)

			M										F									
			<1yr	1-4yrs	5-14yrs	15-24yrs	25-44yrs	45-64yrs	65-74yrs	75-84yrs	85+yrs	All Ages	<1yr	1-4yrs	5-14yrs	15-24yrs	25-44yrs	45-64yrs	65-74yrs	75-84yrs	85+yrs	All Ages
North	Quarter	1	0	0	0	2	5	13	14	16	26	8	0	0	0	2	10	18	23	21	21	12
		2	0	1	0	1	5	11	13	16	15	7	0	1	0	2	11	18	15	19	19	11
		3	0	0	1	0	6	11	15	18	15	7	0	0	0	2	10	19	15	19	14	11
		4	0	0	0	2	5	11	14	18	16	7	0	0	0	4	10	19	16	19	19	12
	Year	18/19	0	1	6	29	239	501	242	165	55	1,238	0	1	3	59	439	787	307	225	97	1,918
	Episodes	F/N	0	0	0	1	5	12	14	17	18	7	0	0	0	3	10	18	17	20	18	12
South	Quarter	1	0	0	0	2	4	12	19	23	24	8	0	1	0	3	11	19	17	27	26	13
		2	0	0	0	1	3	8	14	19	21	6	0	0	0	3	9	17	14	21	21	11
		3	0	0	1	1	4	9	12	26	26	7	0	0	1	2	11	17	14	23	26	12
		4	0	0	0	1	5	12	15	21	17	8	0	0	0	2	13	20	20	26	31	14
	Year	18/19	0	0	7	32	202	525	295	258	96	1,415	0	3	5	57	520	945	351	337	198	2,416
	Episodes	F/N	0	0	0	1	4	10	15	22	22	7	0	0	0	3	11	19	16	24	26	12
London	Quarter	1	0	0	0	3	4	12	14	31	22	6	0	0	0	2	10	26	14	31	17	12
		2	0	0	0	0	4	12	10	25	16	5	0	0	1	2	9	18	15	28	5	9
		3	0	0	1	1	4	8	17	15	15	5	0	0	0	2	9	16	16	22	16	9
		4	0	0	0	1	4	10	12	14	27	5	0	0	0	3	10	21	18	22	14	10
	Year	18/19	0	0	4	17	178	260	68	60	21	608	0	0	6	31	439	451	91	94	23	1,135
	Episodes	F/N	0	0	0	1	4	11	13	21	20	5	0	0	0	2	9	20	16	26	13	10
Midlands And East	Quarter	1	0	0	1	0	3	10	23	28	17	9	0	0	1	2	12	19	12	24	24	13
		2	0	0	0	1	6	9	19	14	17	7	0	0	2	2	11	17	14	17	18	11
		3	0	0	1	2	6	9	13	25	18	8	0	0	0	0	9	20	16	19	19	12
		4	0	0	0	1	6	10	15	13	22	7	0	0	0	1	11	18	13	16	20	11
	Year	18/19	0	0	5	9	107	211	143	96	31	602	0	0	8	11	199	405	120	105	57	905
	Episodes	F/N	0	0	1	1	5	10	18	20	18	8	0	0	1	1	11	19	14	19	20	12

Mean weekly incidence rate per 100,000 Persons.

Meningitis and Encephalitis (ICD10: A170 - A171; A 390; A83 - A85; A87; G00 - G05)

		M										F									
		<1yr	1-4yrs	5-14yrs	15-24yrs	25-44yrs	45-64yrs	65-74yrs	75-84yrs	85+yrs	All Ages	<1yr	1-4yrs	5-14yrs	15-24yrs	25-44yrs	45-64yrs	65-74yrs	75-84yrs	85+yrs	All Ages
4 weekly	1	0.00	0.88	0.18	0.00	0.21	0.14	0.00	0.00	0.00	0.14	0.00	0.41	0.00	0.00	0.07	0.19	0.00	0.00	0.55	0.10
	2	0.00	0.60	0.00	0.00	0.00	0.19	0.25	0.00	0.00	0.10	0.00	1.89	0.00	0.17	0.10	0.16	0.00	0.00	0.00	0.16
	3	0.00	1.07	0.00	0.00	0.08	0.00	0.00	0.00	0.00	0.07	0.00	0.00	0.00	0.18	0.25	0.45	0.22	0.00	0.00	0.24
	4	0.00	0.56	0.00	0.00	0.00	0.07	0.00	0.00	0.00	0.04	0.00	0.00	0.00	0.35	0.07	0.09	0.00	0.75	0.00	0.15
	5	8.39	0.00	0.00	0.00	0.00	0.09	0.00	0.28	0.00	0.06	0.00	0.00	0.00	0.00	0.08	0.14	0.00	0.00	0.00	0.07
	6	0.00	0.00	0.00	0.00	0.00	0.30	0.00	0.67	0.00	0.11	6.83	0.57	0.00	0.15	0.23	0.23	0.00	0.00	0.00	0.19
	7	6.34	0.00	0.00	0.00	0.18	0.14	0.20	0.00	0.00	0.13	0.00	0.52	0.00	0.00	0.18	0.00	0.00	0.00	0.63	0.08
	8	0.00	0.00	0.35	0.14	0.07	0.13	0.18	0.00	0.00	0.12	3.91	0.00	0.00	0.00	0.14	0.35	0.00	0.00	0.00	0.13
	9	10.89	0.00	0.16	0.00	0.00	0.07	0.18	0.00	0.00	0.12	0.00	0.00	0.00	0.39	0.07	0.00	0.00	0.00	0.00	0.08
	10	0.00	0.00	0.00	0.00	0.20	0.06	0.49	0.00	0.00	0.12	6.66	0.00	0.00	0.13	0.28	0.00	0.34	0.00	0.00	0.17
	11	5.51	0.00	0.41	0.00	0.12	0.00	0.00	0.31	0.00	0.14	2.56	0.00	0.00	0.00	0.21	0.00	0.00	0.52	0.00	0.10
	12	2.40	0.38	0.00	0.13	0.00	0.11	0.14	0.31	0.00	0.11	0.00	0.58	0.00	0.12	0.00	0.18	0.12	0.00	0.00	0.11
	13	3.97	0.76	0.00	0.13	0.00	0.11	0.00	0.00	0.00	0.11	6.09	0.00	0.00	0.00	0.13	0.20	0.16	0.00	0.00	0.14
Quarter	1	0.00	0.79	0.06	0.00	0.10	0.11	0.07	0.00	0.00	0.10	0.00	0.68	0.00	0.10	0.13	0.27	0.06	0.00	0.19	0.16
	2	4.53	0.17	0.00	0.00	0.06	0.16	0.06	0.29	0.00	0.10	2.10	0.33	0.00	0.15	0.17	0.11	0.00	0.23	0.19	0.15
	3	3.35	0.00	0.16	0.04	0.08	0.08	0.26	0.00	0.00	0.11	3.25	0.00	0.00	0.16	0.06	0.11	0.00	0.00	0.00	0.08
	4	3.66	0.35	0.13	0.08	0.04	0.09	0.04	0.19	0.00	0.12	2.66	0.18	0.00	0.04	0.19	0.12	0.19	0.16	0.00	0.14
Year	18/19	9.00	8.00	5.00	3.00	8.00	18.00	7.00	5.00	0.00	63.00	7.00	7.00	0.00	10.00	20.00	19.00	4.00	2.00	2.00	71.00
Episodes	F/N	2.83	0.34	0.09	0.03	0.07	0.11	0.11	0.12	0.00	0.11	1.97	0.31	0.00	0.11	0.14	0.15	0.06	0.10	0.10	0.13

Mean weekly incidence rate per 100,000 Persons.

Meningitis and Encephalitis (ICD10: A170 - A171; A 390; A83 - A85; A87; G00 - G05)

			M										F								
			<1yr	1-4yrs	5-14yrs	15-24yrs	25-44yrs	45-64yrs	65-74yrs	75-84yrs	85+yrs	All Ages	<1yr	1-4yrs	5-14yrs	15-24yrs	25-44yrs	45-64yrs	65-74yrs	75-84yrs	85+yrs	All Ages
North	Quarter	1	0.00	0.68	0.25	0.00	0.00	0.32	0.28	0.00	0.00	0.17	0.00	1.49	0.00	0.40	0.33	0.32	0.25	0.00	0.78	0.33
		2	0.00	0.68	0.00	0.00	0.00	0.21	0.25	0.46	0.00	0.13	0.00	1.34	0.00	0.61	0.10	0.00	0.00	0.00	0.78	0.19
		3	5.04	0.00	0.20	0.00	0.00	0.18	0.45	0.00	0.00	0.14	4.14	0.00	0.00	0.47	0.00	0.00	0.00	0.00	0.00	0.08
		4	6.28	1.41	0.00	0.31	0.00	0.15	0.00	0.76	0.00	0.23	3.15	0.00	0.00	0.15	0.08	0.08	0.20	0.00	0.00	0.10
	Year	18/19	3.00	5.00	2.00	2.00	0.00	9.00	4.00	3.00	0.00	28.00	2.00	4.00	0.00	9.00	5.00	4.00	2.00	0.00	2.00	28.00
	Episodes	F/N	2.78	0.69	0.11	0.08	0.00	0.22	0.25	0.30	0.00	0.17	1.79	0.72	0.00	0.41	0.13	0.10	0.11	0.00	0.40	0.18
South	Quarter	1	0.00	1.26	0.00	0.00	0.09	0.10	0.00	0.00	0.00	0.10	0.00	0.58	0.00	0.00	0.09	0.18	0.00	0.00	0.00	0.09
		2	10.33	0.00	0.00	0.00	0.00	0.25	0.00	0.71	0.00	0.13	8.41	0.00	0.00	0.00	0.09	0.25	0.00	0.00	0.00	0.11
		3	4.15	0.00	0.00	0.17	0.16	0.00	0.19	0.00	0.00	0.10	4.82	0.00	0.00	0.16	0.09	0.07	0.00	0.00	0.00	0.08
		4	0.00	0.00	0.15	0.00	0.14	0.19	0.17	0.00	0.00	0.12	2.27	0.00	0.00	0.00	0.15	0.07	0.15	0.00	0.00	0.09
	Year	18/19	2.00	2.00	1.00	1.00	5.00	7.00	2.00	2.00	0.00	22.00	3.00	1.00	0.00	1.00	5.00	7.00	1.00	0.00	0.00	18.00
	Episodes	F/N	3.55	0.33	0.04	0.04	0.10	0.13	0.09	0.17	0.00	0.11	3.80	0.15	0.00	0.04	0.10	0.14	0.04	0.00	0.00	0.09
London	Quarter	1	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.67	0.00	0.00	0.09	0.37	0.00	0.00	0.00	0.15
		2	7.80	0.00	0.00	0.00	0.00	0.18	0.00	0.00	0.00	0.08	0.00	0.00	0.00	0.00	0.28	0.00	0.00	0.00	0.00	0.11
		3	4.21	0.00	0.00	0.00	0.00	0.16	0.00	0.00	0.00	0.07	4.05	0.00	0.00	0.00	0.16	0.36	0.00	0.00	0.00	0.17
		4	3.46	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.03	0.00	0.71	0.00	0.00	0.00	0.17	0.00	0.00	0.00	0.07
	Year	18/19	3.00	0.00	0.00	0.00	0.00	2.00	0.00	0.00	0.00	5.00	1.00	2.00	0.00	0.00	6.00	5.00	0.00	0.00	0.00	14.00
	Episodes	F/N	3.79	0.00	0.00	0.00	0.00	0.08	0.00	0.00	0.00	0.04	0.99	0.35	0.00	0.00	0.13	0.23	0.00	0.00	0.00	0.13
Midlands And East	Quarter	1	0.00	1.23	0.00	0.00	0.30	0.00	0.00	0.00	0.00	0.12	0.00	0.00	0.00	0.00	0.00	0.20	0.00	0.00	0.00	0.06
		2	0.00	0.00	0.00	0.00	0.22	0.00	0.00	0.00	0.00	0.05	0.00	0.00	0.00	0.00	0.22	0.19	0.00	0.92	0.00	0.17
		3	0.00	0.00	0.42	0.00	0.17	0.00	0.42	0.00	0.00	0.14	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
		4	4.89	0.00	0.36	0.00	0.00	0.00	0.00	0.00	0.00	0.09	5.22	0.00	0.00	0.00	0.53	0.16	0.41	0.64	0.00	0.30
	Year	18/19	1.00	1.00	2.00	0.00	3.00	0.00	1.00	0.00	0.00	8.00	1.00	0.00	0.00	0.00	4.00	3.00	1.00	2.00	0.00	11.00
	Episodes	F/N	1.20	0.32	0.19	0.00	0.17	0.00	0.10	0.00	0.00	0.10	1.28	0.00	0.00	0.00	0.18	0.14	0.10	0.38	0.00	0.13

4 weekly periods(2018-2019)

1	07/05/2018	-	03/06/2018
2	04/06/2018	-	01/07/2018
3	02/07/2018	-	29/07/2018
4	30/07/2018	-	26/08/2018
5	27/08/2018	-	23/09/2018
6	24/09/2018	-	21/10/2018
7	22/10/2018	-	18/11/2018
8	19/11/2018	-	16/12/2018
9	17/12/2018	-	13/01/2019
10	14/01/2019	-	10/02/2019
11	11/02/2019	-	10/03/2019
12	11/03/2019	-	07/04/2019
13	08/04/2019	-	05/05/2019

Quarterly Periods

1st	07/05/2018 – 29/07/2018
2nd	30/07/2018 – 21/10/2018
3rd	22/10/2018 – 13/01/2019
4th	14/01/2019 – 05/05/2019

Age Sex Breakdown, National

	<1yr	1-4yrs	5-14yrs	15-24yrs	25-44yrs	45-64yrs	65-74yrs	75-84yrs	85+yrs
Female	13,001	71,647	181,401	198,797	459,952	396,181	156,181	101,378	54,423
Male	13,814	74,975	191,120	192,301	459,772	409,181	146,578	85,156	31,882